David W Denning

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/299534/publications.pdf

Version: 2024-02-01

662 papers	73,746 citations	1296 112 h-index	832 252 g-index
693 all docs	693 docs citations	693 times ranked	35941 citing authors

#	Article	IF	Citations
1	Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical Infectious Diseases, 2008, 46, 1813-1821.	2.9	4,375
2	Hidden Killers: Human Fungal Infections. Science Translational Medicine, 2012, 4, 165rv13.	5.8	3,368
3	Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis. New England Journal of Medicine, 2002, 347, 408-415.	13.9	3,048
4	Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America. Clinical Infectious Diseases, 2008, 46, 327-360.	2.9	2,432
5	Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus. Clinical Infectious Diseases, 2002, 34, 7-14.	2.9	2,255
6	Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2016, 63, e1-e60.	2.9	1,861
7	Global and Multi-National Prevalence of Fungal Diseasesâ€"Estimate Precision. Journal of Fungi (Basel,) Tj ETQq1 1 0.784314 rgBT /Ov	1.5	1,842
8	Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infectious Diseases, The, 2017, 17, 873-881.	4.6	1,559
9	Invasive Aspergillosis. Clinical Infectious Diseases, 1998, 26, 781-803.	2.9	1,522
10	Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus. Nature, 2005, 438, 1151-1156.	13.7	1,272
11	Sequencing of Aspergillus nidulans and comparative analysis with A. fumigatus and A. oryzae. Nature, 2005, 438, 1105-1115.	13.7	1,250
12	Genome sequencing and analysis of Aspergillus oryzae. Nature, 2005, 438, 1157-1161.	13.7	1,128
13	Echinocandin antifungal drugs. Lancet, The, 2003, 362, 1142-1151.	6.3	970
14	Antifungal and Surgical Treatment of Invasive Aspergillosis: Review of 2,121 Published Cases. Clinical Infectious Diseases, 1990, 12, 1147-1201.	2.9	834
15	Efficacy and Safety of Voriconazole in the Treatment of Acute Invasive Aspergillosis. Clinical Infectious Diseases, 2002, 34, 563-571.	2.9	807
16	Practice Guidelines for Diseases Caused by Aspergillus. Clinical Infectious Diseases, 2000, 30, 696-709.	2.9	757
17	Aspergillus flavus: human pathogen, allergen and mycotoxin producer. Microbiology (United) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.7	716
18	The link between fungi and severe asthma: a summary of the evidence. European Respiratory Journal, 2006, 27, 615-626.	3.1	703

#	Article	IF	Citations
19	Frequency and Evolution of Azole Resistance inAspergillus fumigatusAssociated with Treatment Failure1. Emerging Infectious Diseases, 2009, 15, 1068-1076.	2.0	692
20	Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clinical and Experimental Allergy, 2013, 43, 850-873.	1.4	666
21	Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosisâ€"State of the Art: Cystic Fibrosis Foundation Consensus Conference. Clinical Infectious Diseases, 2003, 37, S225-S264.	2.9	658
22	Therapeutic Outcome in Invasive Aspergillosis. Clinical Infectious Diseases, 1996, 23, 608-615.	2.9	656
23	Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. European Respiratory Journal, 2016, 47, 45-68.	3.1	654
24	Efficacy and Safety of Caspofungin for Treatment of Invasive Aspergillosis in Patients Refractory to or Intolerant of Conventional Antifungal Therapy. Clinical Infectious Diseases, 2004, 39, 1563-1571.	2.9	617
25	The clinical spectrum of pulmonary aspergillosis. Thorax, 2015, 70, 270-277.	2.7	611
26	Increasing Volume and Changing Characteristics of Invasive Pulmonary Aspergillosis on Sequential Thoracic Computed Tomography Scans in Patients With Neutropenia. Journal of Clinical Oncology, 2001, 19, 253-259.	0.8	544
27	Tackling Human Fungal Infections. Science, 2012, 336, 647-647.	6.0	531
28	Imaging Findings in Acute Invasive Pulmonary Aspergillosis: Clinical Significance of the Halo Sign. Clinical Infectious Diseases, 2007, 44, 373-379.	2.9	524
29	Pulmonary Aspergillosis in the Acquired Immunodeficiency Syndrome. New England Journal of Medicine, 1991, 324, 654-662.	13.9	509
30	NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. American Journal of Medicine, 1994, 97, 135-144.	0.6	474
31	Genomic Islands in the Pathogenic Filamentous Fungus Aspergillus fumigatus. PLoS Genetics, 2008, 4, e1000046.	1.5	473
32	Itraconazole resistance in Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 1997, 41, 1364-1368.	1.4	457
33	Chronic Cavitary and Fibrosing Pulmonary and Pleural Aspergillosis: Case Series, Proposed Nomenclature Change, and Review. Clinical Infectious Diseases, 2003, 37, S265-S280.	2.9	456
34	EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clinical Microbiology and Infection, 2008, 14, 398-405.	2.8	447
35	Laboratory diagnosis of invasive aspergillosis. Lancet Infectious Diseases, The, 2005, 5, 609-622.	4.6	432
36	Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. Journal of Antimicrobial Chemotherapy, 2012, 67, 269-289.	1.3	428

#	Article	IF	Citations
37	How to bolster the antifungal pipeline. Science, 2015, 347, 1414-1416.	6.0	416
38	Fungi and allergic lower respiratory tract diseases. Journal of Allergy and Clinical Immunology, 2012, 129, 280-291.	1.5	398
39	Treatment of invasive aspergillosis with itraconazole. American Journal of Medicine, 1989, 86, 791-800.	0.6	393
40	Fungal rhinosinusitis. Laryngoscope, 2009, 119, 1809-1818.	1.1	385
41	Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Medical Mycology, 2013, 51, 361-370.	0.3	384
42	Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. European Respiratory Journal, 2011, 37, 865-872.	3.1	355
43	Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infectious Diseases, The, 2018, 18, e339-e347.	4.6	334
44	EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidiaâ€“forming moulds. Clinical Microbiology and Infection, 2008, 14, 982-984.	2.8	323
45	Randomized Controlled Trial of Oral Antifungal Treatment for Severe Asthma with Fungal Sensitization. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 11-18.	2.5	320
46	Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bulletin of the World Health Organization, 2011, 89, 864-872.	1.5	318
47	Prospective Multicenter International Surveillance of Azole Resistance inAspergillus fumigatus. Emerging Infectious Diseases, 2015, 21, 1041-1044.	2.0	302
48	In vitro susceptibilities of zygomycetes to conventional and new antifungals. Journal of Antimicrobial Chemotherapy, 2003, 51, 45-52.	1.3	299
49	Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2016, 63, 433-442.	2.9	295
50	Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. Journal of Infection, 2006, 53, 337-349.	1.7	290
51	Aspergillosis. Infectious Disease Clinics of North America, 2002, 16, 875-894.	1.9	284
52	Evidence for Sexuality in the Opportunistic Fungal Pathogen Aspergillus fumigatus. Current Biology, 2005, 15, 1242-1248.	1.8	283
53	Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. Journal of Antimicrobial Chemotherapy, 2010, 65, 2116-2118.	1.3	279
54	Threats Posed by the Fungal Kingdom to Humans, Wildlife, and Agriculture. MBio, 2020, 11, .	1.8	275

#	Article	IF	Citations
55	Therapy for fungal diseases: opportunities and priorities. Trends in Microbiology, 2010, 18, 195-204.	3.5	268
56	High-frequency Triazole Resistance Found In Nonculturable Aspergillus fumigatus from Lungs of Patients with Chronic Fungal Disease. Clinical Infectious Diseases, 2011, 52, 1123-1129.	2.9	264
57	Fungal allergy in asthmaâ€“state of the art and research needs. Clinical and Translational Allergy, 2014, 4, 14.	1.4	264
58	International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resistance Updates, 2015, 21-22, 30-40.	6.5	262
59	Ulcerative Tracheobronchitis after Lung Transplantation: A New Form of Invasive Aspergillosis. The American Review of Respiratory Disease, 1991, 144, 552-556.	2.9	257
60	An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: Diagnosis and therapeutic outcome. Journal of Infection, 1998, 37, 173-180.	1.7	250
61	Echinocandins: a new class of antifungal. Journal of Antimicrobial Chemotherapy, 2002, 49, 889-891.	1.3	247
62	The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in Aspergillus fumigatusÂ. Journal of Antimicrobial Chemotherapy, 2013, 68, 1486-1496.	1.3	243
63	In Vitro Activities of New and Conventional Antifungal Agents against Clinical Scedosporium Isolates. Antimicrobial Agents and Chemotherapy, 2002, 46, 62-68.	1.4	230
64	Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome. American Journal of Medicine, 1991, 91, 267-272.	0.6	222
65	Azole-resistance in Aspergillus: Proposed nomenclature and breakpoints. Drug Resistance Updates, 2009, 12, 141-147.	6.5	222
66	Polymorphisms in Tollâ€Like Receptor Genes and Susceptibility to Pulmonary Aspergillosis. Journal of Infectious Diseases, 2008, 197, 618-621.	1.9	220
67	Interaction of Azoles with Rifampin, Phenytoin, and Carbamazepine: In Vitro and Clinical Observations. Clinical Infectious Diseases, 1992, 14, 165-174.	2.9	206
68	Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. Journal of Antimicrobial Chemotherapy, 1997, 40, 401-414.	1.3	202
69	Adjunctive Therapy of Allergic Bronchopulmonary Aspergillosis with Itraconazole. Chest, 1991, 100, 813-819.	0.4	201
70	Mold sensitization is common amongst patients with severe asthma requiring multiple hospital admissions. BMC Pulmonary Medicine, 2005, 5, 4.	0.8	199
71	Multi-azole resistance in Aspergillus fumigatus. International Journal of Antimicrobial Agents, 2006, 28, 450-453.	1.1	199
72	The invasive and saprophytic syndromes due toAspergillusspp.. Medical Mycology, 2005, 43, 207-238.	0.3	194

#	Article	IF	Citations
73	Adverse events associated with itraconazole in 189 patients on chronic therapy. Journal of Antimicrobial Chemotherapy, 1990, 26, 561-566.	1.3	193
74	British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet Infectious Diseases, The, 2003, 3, 230-240.	4.6	185
75	Novel immunologic classification of aspergillosis in adult cystic fibrosis. Journal of Allergy and Clinical Immunology, 2013, 132, 560-566.e10.	1.5	180
76	Adverse Reactions to Voriconazole. Clinical Infectious Diseases, 2004, 39, 1241-1244.	2.9	177
77	Autoantibodies against Type I Interferons as an Additional Diagnostic Criterion for Autoimmune Polyendocrine Syndrome Type I. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4389-4397.	1.8	176
78	Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate. Fungal Genetics and Biology, 2002, 36, 199-206.	0.9	174
79	Itraconazole Therapy for Cryptococcal Meningitis and Cryptococcosis. Archives of Internal Medicine, 1989, 149, 2301.	4.3	173
80	Multilocus Sequence Typing of Candidaglabrata Reveals Geographically EnrichedClades. Journal of Clinical Microbiology, 2003, 41, 5709-5717.	1.8	172
81	The global incidence and diagnosis of fungal keratitis. Lancet Infectious Diseases, The, 2021, 21, e49-e57.	4.6	172
82	Combination and Sequential Antifungal Therapy for Invasive Aspergillosis: Review of Published In Vitro and In Vivo Interactions and 6281 Clinical Cases from 1966 to 2001. Clinical Infectious Diseases, 2003, 37, S188-S224.	2.9	169
83	Aspergillus Fungemia: Report of Two Cases and Review. Clinical Infectious Diseases, 1995, 20, 598-605.	2.9	163
84	Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?. Journal of Antimicrobial Chemotherapy, 2006, 57, 384-410.	1.3	157
85	New and emerging treatments for fungal infections. Journal of Antimicrobial Chemotherapy, 2008, 61, i19-i30.	1.3	157
86	British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases. Lancet Infectious Diseases, The, 2015, 15, 461-474.	4.6	155
87	Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation. European Journal of Clinical Microbiology and Infectious Diseases, 1997, 16, 424-436.	1.3	152
88	Pulmonary cryptococcosis: A review of pathobiology and clinical aspects. Medical Mycology, 2019, 57, 133-150.	0.3	152
89	Comparison of skin prick tests with specific serum immunoglobulin E in the diagnosis of fungal sensitization in patients with severe asthma. Clinical and Experimental Allergy, 2009, 39, 1677-1683.	1.4	148
90	Re-drawing the Maps for Endemic Mycoses. Mycopathologia, 2020, 185, 843-865.	1.3	148

#	Article	IF	Citations
91	Antifungal Drug Resistance in Aspergillus. Journal of Infection, 2000, 41, 203-220.	1.7	147
92	Global burden of chronic pulmonary aspergillosis complicating sarcoidosis. European Respiratory Journal, 2013, 41, 621-626.	3.1	147
93	Mannoseâ€Binding Lectin Gene Polymorphisms as a Susceptibility Factor for Chronic Necrotizing Pulmonary Aspergillosis. Journal of Infectious Diseases, 2001, 184, 653-656.	1.9	145
94	High prevalence of antifungal resistance in Candida spp. from patients with AIDS. Journal of Antimicrobial Chemotherapy, 1994, 34, 659-668.	1.3	144
95	Post-operative aspergillosis. Clinical Microbiology and Infection, 2006, 12, 1060-1076.	2.8	144
96	In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagnostic Microbiology and Infectious Disease, 1992, 15, 21-34.	0.8	140
97	Itraconazole Therapy for Chronic Coccidioidal Meningitis. Annals of Internal Medicine, 1990, 112, 108.	2.0	139
98	Molecular Mechanisms of Primary Resistance to Flucytosine in Candida albicans. Antimicrobial Agents and Chemotherapy, 2004, 48, 4377-4386.	1.4	139
99	Invasive Aspergillosis in Patients with AIDS. Clinical Infectious Diseases, 1994, 19, S41-S48.	2.9	137
100	Pathogenicity ofAspergillus fumigatusmutants assessed inGalleria mellonellamatches that in mice. Medical Mycology, 2011, 49, S107-S113.	0.3	137
101	Fluconazole-resistant candidosis in an HIV cohort. Aids, 1994, 8, 787-792.	1.0	136
102	Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clinical Microbiology and Infection, 2003, 9, 467-474.	2.8	135
103	Restriction Endonuclease Analysis of Total Cellular DNA of Aspergillus fumigatus Isolates of Geographically and Epidemiologically Diverse Origin. Journal of Infectious Diseases, 1990, 162, 1151-1158.	1.9	134
104	Sequencing of mitochondrial genomes of nine Aspergillus and Penicillium species identifies mobile introns and accessory genes as main sources of genome size variability. BMC Genomics, 2012, 13, 698.	1.2	131
105	Cyclosporine and Itraconazole Interaction in Heart and Lung Transplant Recipients. Annals of Internal Medicine, 1990, 113, 327.	2.0	130
106	Therapeutic drug monitoring for triazoles. Current Opinion in Infectious Diseases, 2008, 21, 580-586.	1.3	128
107	Histoplasmosis in Africa: An emerging or a neglected disease?. PLoS Neglected Tropical Diseases, 2018, 12, e0006046.	1.3	125
108	Efficacy and Safety of Posaconazole for Chronic Pulmonary Aspergillosis. Clinical Infectious Diseases, 2010, 51, 1383-1391.	2.9	123

#	Article	IF	Citations
109	Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clinical and Experimental Dermatology, 2001, 26, 648-653.	0.6	122
110	Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts. Clinical Microbiology and Infection, 2003, 9, i-viii.	2.8	122
111	Global access to antifungal therapy and its variable cost. Journal of Antimicrobial Chemotherapy, 2016, 71, 3599-3606.	1.3	122
112	Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host. Journal of Antimicrobial Chemotherapy, 1991, 28, 1-16.	1.3	122
113	Administering amphotericin Bâ€”a practical approach. Journal of Antimicrobial Chemotherapy, 1994, 33, 203-213.	1.3	121
114	Predictors of mortality in chronic pulmonary aspergillosis. European Respiratory Journal, 2017, 49, 1601062.	3.1	120
115	Echinocandins and pneumocandins–a new antifungal class with a novel mode of action. Journal of Antimicrobial Chemotherapy, 1997, 40, 611-614.	1.3	119
116	Azole Cross-Resistance in Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 2002, 46, 556-557.	1.4	117
117	Toxicodynamics of Itraconazole: Implications for Therapeutic Drug Monitoring. Clinical Infectious Diseases, 2009, 49, 928-930.	2.9	116
118	Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transplant Infectious Disease, 2009, 11, 89-93.	0.7	116
119	Voriconazole and Posaconazole Improve Asthma Severity in Allergic Bronchopulmonary Aspergillosis and Severe Asthma with Fungal Sensitization. Journal of Asthma, 2012, 49, 423-433.	0.9	116
120	Cryptic Species and Azole Resistance in the Aspergillus niger Complex. Antimicrobial Agents and Chemotherapy, 2011, 55, 4802-4809.	1.4	112
121	Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 1997, 41, 1504-1507.	1.4	111
122	Comparison of six Aspergillus-specific IgG assays for the diagnosis of chronic pulmonary aspergillosis (CPA). Journal of Infection, 2016, 72, 240-249.	1.7	110
123	Endemic mycoses: a treatment update. Journal of Antimicrobial Chemotherapy, 1999, 43, 321-331.	1.3	107
124	Strategy of Following Voriconazole versus Amphotericin B Therapy with Other Licensed Antifungal Therapy for Primary Treatment of Invasive Aspergillosis: Impact of Other Therapies on Outcome. Clinical Infectious Diseases, 2005, 41, 1448-1452.	2.9	106
125	Invasive yeast infections other than Candida spp. in acute leukaemia. Journal of Hospital Infection, 1999, 41, 181-194.	1.4	103
126	Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residualÂcavitation. European Respiratory Journal, 2019, 53, 1801184.	3.1	103

#	Article	IF	Citations
127	In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrobial Agents and Chemotherapy, 1997, 41, 1124-1126.	1.4	101
128	Efficacy of LY303366 against Amphotericin B-Susceptible and -Resistant Aspergillus fumigatus in a Murine Model of Invasive Aspergillosis. Antimicrobial Agents and Chemotherapy, 1998, 42, 873-878.	1.4	101
129	Invasive Infection due to Penicillium Species other than P. marneffei. Journal of Infection, 2002, 45, 184-195.	1.7	101
130	Distinct alleles of mannose-binding lectin (MBL) and surfactant proteins A (SP-A) in patients with chronic cavitary pulmonary aspergillosis and allergic bronchopulmonary aspergillosis. Clinical Chemistry and Laboratory Medicine, 2007, 45, 183-6.	1.4	98
131	The burden of serious human fungal infections in Brazil. Mycoses, 2016, 59, 145-150.	1.8	98
132	Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis. European Respiratory Journal, 2020, 56, 2002554.	3.1	98
133	Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. Journal of Antimicrobial Chemotherapy, 2000, 45, 85-93.	1.3	96
134	Candida tropicalisin human disease. Critical Reviews in Microbiology, 2010, 36, 282-298.	2.7	96
135	Estimation of the Burden of Chronic and Allergic Pulmonary Aspergillosis in India. PLoS ONE, 2014, 9, e114745.	1.1	95
136	Voriconazole Treatment for Subacute Invasive and Chronic Pulmonary Aspergillosis. American Journal of Medicine, 2006, 119, 527.e17-527.e24.	0.6	94
137	Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options. Lancet Infectious Diseases, The, 2014, 14, 1136-1149.	4.6	91
138	Transplacental transfer of aflatoxin in humans. Carcinogenesis, 1990, 11, 1033-1035.	1.3	90
139	Multi-Country Estimate of Different Manifestations of Aspergillosis in Cystic Fibrosis. PLoS ONE, 2014, 9, e98502.	1.1	90
140	Fluconazole resistance in Candida in patients with AIDSâ€"A therapeutic approach. Journal of Infection, 1993, 26, 117-125.	1.7	89
141	Azole resistance inAspergillus: a growing public health menace. Future Microbiology, 2011, 6, 1229-1232.	1.0	89
142	Case Definition of Chronic Pulmonary Aspergillosis in Resource-Constrained Settings. Emerging Infectious Diseases, 2018, 24, .	2.0	89
143	Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500 000 by 2020 to be realized. Philosophical Transactions of the Royal Society B: Biological Sciences, 2016, 371, 20150468.	1.8	88
144	Interrogation of Related Clinical Pan-Azole-Resistant Aspergillus fumigatus Strains: G138C, Y431C, and G434C Single Nucleotide Polymorphisms in cyp51A , Upregulation of cyp51A , and Integration and Activation of Transposon Atf1 in the cyp51A Promoter. Antimicrobial Agents and Chemotherapy, 2011, 55, 5113-5121.	1.4	87

#	Article	IF	Citations
145	Results of surgery for chronic pulmonary Aspergillosis, optimal antifungal therapy and proposed high risk factors for recurrence - a National Centreâ€™s experience. Journal of Cardiothoracic Surgery, 2013, 8, 180.	0.4	87
146	In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 7	1.3	86
147	A Cautionary Tale: Lack of Consistency in Allele Sizes between Two Laboratories for a Published Multilocus Microsatellite Typing System. Journal of Clinical Microbiology, 2007, 45, 522-528.	1.8	85
148	Treatment of Coccidioidal Meningitis with Fluconazole. Clinical Infectious Diseases, 1990, 12, S380-S389.	2.9	84
149	Multicenter, Prospective Clinical Evaluation of Respiratory Samples from Subjects at Risk for Pneumocystis jirovecii Infection by Use of a Commercial Real-Time PCR Assay. Journal of Clinical Microbiology, 2011, 49, 1872-1878.	1.8	84
150	Pulmonary and sinus fungal diseases in non-immunocompromised patients. Lancet Infectious Diseases, The, 2017, 17, e357-e366.	4.6	84
151	Itraconazole therapy for nonmeningeal coccidioidomycosis: Clinical and laboratory observations. Journal of the American Academy of Dermatology, 1990, 23, 593-601.	0.6	83
152	What can comparative genomics tell us about species concepts in the genus Aspergillus?. Studies in Mycology, 2007, 59, 11-17.	4.5	83
153	EUCAST Technical Note on fluconazole. Clinical Microbiology and Infection, 2008, 14, 193-195.	2.8	83
154	Molecular Detection and Identification of Zygomycetes Species from Paraffin-Embedded Tissues in a Murine Model of Disseminated Zygomycosis: a Collaborative European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) Evaluation. Journal of Clinical Microbiology, 2010, 48, 2043-2046.	1.8	83
155	Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis.. Antimicrobial Agents and Chemotherapy, 1991, 35, 1329-1333.	1.4	81
156	Sequencing the Aspergillus fumigatus genome. Lancet Infectious Diseases, The, 2002, 2, 251-253.	4.6	81
157	Antibody testing in aspergillosisâ€”quo vadis?. Medical Mycology, 2015, 53, 417-439.	0.3	81
158	Evidence of multiple extracellular phospholipase activities of Aspergillus fumigatus. Infection and Immunity, 1996, 64, 751-755.	1.0	81
159	Molecular typing by random amplification of polymorphic DNA and M13 southern hybridization of related paired isolates of Aspergillus fumigatus. Journal of Clinical Microbiology, 1996, 34, 87-93.	1.8	80
160	In Vitro Activity of the Echinocandin Antifungal Agent LY303,366 in Comparison with Itraconazole and Amphotericin B against Aspergillus spp. Antimicrobial Agents and Chemotherapy, 1998, 42, 2726-2730.	1.4	79
161	Pathophysiological aspects ofAspergilluscolonization in disease. Medical Mycology, 2019, 57, S219-S227.	0.3	79
162	Molecular genetics in Aspergillus fumigatus. Current Opinion in Microbiology, 2000, 3, 468-474.	2.3	78

#	Article	IF	Citations
163	In Vitro Susceptibilities of Zygomycetes to Combinations of Antimicrobial Agents. Antimicrobial Agents and Chemotherapy, 2002, 46, 2708-2711.	1.4	78
164	The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. Journal of Infection, 2006, 52, e133-e137.	1.7	78
165	Performance of two Aspergillus IgG EIA assays compared with the precipitin test in chronic and allergic aspergillosis. Clinical Microbiology and Infection, 2013, 19, E197-E204.	2.8	78
166	Pharmacokinetics and Pharmacodynamics of a Novel Triazole, Isavuconazole: Mathematical Modeling, Importance of Tissue Concentrations, and Impact of Immune Status on Antifungal Effect. Antimicrobial Agents and Chemotherapy, 2009, 53, 3453-3461.	1.4	77
167	Corticosteroid treatment is associated with increased filamentous fungal burden in allergic fungal disease. Journal of Allergy and Clinical Immunology, 2018, 142, 407-414.	1.5	76
168	Resistance to fluconazole inCandida albicansfrom AIDS patients correlated with reduced intracellular accumulation of drug. FEMS Microbiology Letters, 1995, 131, 337-341.	0.7	74
169	Cytokine profiling of pulmonary aspergillosis. International Journal of Immunogenetics, 2006, 33, 297-302.	0.8	74
170	Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus. Journal of Antimicrobial Chemotherapy, 2006, 58, 1198-1207.	1.3	73
171	High-level expression of cyp51B in azole-resistant clinical Aspergillus fumigatus isolates. Journal of Antimicrobial Chemotherapy, 2013, 68, 512-514.	1.3	73
172	Environmental fungicides and triazole resistance in Aspergillus. Pest Management Science, 2014, 70, 173-178.	1.7	73
173	Azole resistance in allergic bronchopulmonary aspergillosis and Aspergillus bronchitis. Clinical Microbiology and Infection, 2010, 16, 683-688.	2.8	72
174	Allergic Bronchopulmonary Aspergillosis and Related Allergic Syndromes. Seminars in Respiratory and Critical Care Medicine, 2011, 32, 682-692.	0.8	72
175	Estimating the burden of invasive and serious fungal disease in the United Kingdom. Journal of Infection, 2017, 74, 60-71.	1.7	72
176	In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates.. Journal of Antimicrobial Chemotherapy, 1998, 42, 389-392.	1.3	71
177	IgE-Mediated Immune Responses and Airway Detection of Aspergillus and Candida in Adult Cystic Fibrosis. Chest, 2013, 143, 1351-1357.	0.4	71
178	An estimation of burden of serious fungal infections in France. Journal De Mycologie Medicale, 2016, 26, 385-390.	0.7	71
179	Inactivation of Transcription Factor Gene ACE2 in the Fungal Pathogen Candida glabrata Results in Hypervirulence. Eukaryotic Cell, 2004, 3, 546-552.	3.4	70
180	In Vitro Activity of the New Triazole BMS-207147 against Aspergillus Species in Comparison with Itraconazole and Amphotericin B. Antimicrobial Agents and Chemotherapy, 2000, 44, 441-443.	1.4	69

#	Article	IF	Citations
181	Interlaboratory Evaluation of Hematocytometer Method of Inoculum Preparation for Testing Antifungal Susceptibilities of Filamentous Fungi. Journal of Clinical Microbiology, 2003, 41, 5236-5237.	1.8	69
182	Aspergillus bronchitis without significant immunocompromise. Annals of the New York Academy of Sciences, 2012, 1272, 73-85.	1.8	69
183	Performance of cryptococcus antigen latex agglutination kits on serum and cerebrospinal fluid specimens of AIDS patients before and after pronase treatment. Journal of Clinical Microbiology, 1991, 29, 333-339.	1.8	69
184	Need for Alternative Trial Designs and Evaluation Strategies for Therapeutic Studies of Invasive Mycoses. Clinical Infectious Diseases, 2001, 33, 95-106.	2.9	68
185	Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. Journal of Antimicrobial Chemotherapy, 2003, 51, 913-919.	1.3	68
186	Evidence for recombination in Candida glabrata. Fungal Genetics and Biology, 2005, 42, 233-243.	0.9	68
187	Comparative genomics of fungal allergens and epitopes shows widespread distribution of closely related allergen and epitope orthologues. BMC Genomics, 2006, 7, 251.	1.2	68
188	Excess mortality, length of stay and cost attributable to candidaemia. Journal of Infection, 2009, 59, 360-365.	1.7	68
189	Long-term Antifungal Treatment Improves Health Status in Patients With Chronic Pulmonary Aspergillosis: A Longitudinal Analysis. Clinical Infectious Diseases, 2013, 57, 828-835.	2.9	68
190	Twelve-month clinical outcomes of 206 patients with chronic pulmonary aspergillosis. PLoS ONE, 2018, 13, e0193732.	1.1	68
191	The one health problem of azole resistance in Aspergillus fumigatus: current insights and future research agenda. Fungal Biology Reviews, 2020, 34, 202-214.	1.9	68
192	Commentary: unusual manifestations of aspergillosis.. Thorax, 1995, 50, 812-813.	2.7	66
193	In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp.. Journal of Antimicrobial Chemotherapy, 2002, 50, 189-194.	1.3	66
194	Validation of an Assay for Voriconazole in Serum Samples Using Liquid Chromatography-Tandem Mass Spectrometry. Therapeutic Drug Monitoring, 2004, 26, 650-657.	1.0	66
195	Volume dependency for culture of fungi from respiratory secretions and increased sensitivity of <scp>A</scp>spergillus quantitative <scp>PCR</scp>. Mycoses, 2014, 57, 69-78.	1.8	66
196	Oxygen requirements of Aspergillus species. Journal of Medical Microbiology, 1994, 41, 311-315.	0.7	65
197	Commentaries: Name Changes in Medically Important Fungi and Their Implications for Clinical Practice. Journal of Clinical Microbiology, 2015, 53, 1056-1062.	1.8	65
198	Delivering on Antimicrobial Resistance Agenda Not Possible without Improving Fungal Diagnostic Capabilities. Emerging Infectious Diseases, 2017, 23, 177-183.	2.0	65

#	Article	IF	Citations
199	Early diagnosis of invasive aspergillosis. Lancet, The, 2000, 355, 423-424.	6.3	64
200	Candida glabrata STE12 is required for wild-type levels of virulence and nitrogen starvation induced filamentation. Molecular Microbiology, 2003, 50, 1309-1318.	1.2	64
201	Infrared body temperature measurement of mice as an early predictor of death in experimental fungal infections. Laboratory Animals, 2003, 37, 126-131.	0.5	64
202	A Review of Onychomycosis Due to Aspergillus Species. Mycopathologia, 2018, 183, 485-493.	1.3	63
203	Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. Lancet Infectious Diseases, The, 2019, 19, e143-e147.	4.6	63
204	Treatment of invasive aspergillosis. Journal of Infection, 1994, 28, 25-33.	1.7	62
205	The effects of antifungal therapy on severe asthma with fungal sensitization and allergic bronchopulmonary aspergillosis. Respirology, 2009, 14, 1121-1127.	1.3	62
206	Intravenous antibiotics reduce the presence ofAspergillusin adult cystic fibrosis sputum. Thorax, 2013, 68, 652-657.	2.7	62
207	Comparison of In Vitro Activity of Liposomal Nystatin against Aspergillus Species with Those of Nystatin, Amphotericin B (AB) Deoxycholate, AB Colloidal Dispersion, Liposomal AB, AB Lipid Complex, and Itraconazole. Antimicrobial Agents and Chemotherapy, 1999, 43, 1264-1266.	1.4	61
208	Fungal contamination of bedding. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 140-142.	2.7	61
209	Flucytosine therapeutic monitoring: 15 years experience from the UK. Journal of Antimicrobial Chemotherapy, 2007, 59, 791-793.	1.3	61
210	Aspergillus nodules; another presentation of Chronic Pulmonary Aspergillosis. BMC Pulmonary Medicine, 2016, 16, 123.	0.8	61
211	Chronic pulmonary aspergillosis as a cause of smear-negative TB and/or TB treatment failure in Nigerians. International Journal of Tuberculosis and Lung Disease, 2017, 21, 1056-1061.	0.6	61
212	Itraconazole in opportunistic mycoses: Cryptococcosis and aspergillosis. Journal of the American Academy of Dermatology, 1990, 23, 602-607.	0.6	60
213	Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance. Antimicrobial Agents and Chemotherapy, 1996, 40, 2443-2446.	1.4	60
214	Comparison of the Etest and the Sensititre Colorimetric Methods with the NCCLS Proposed Standard for Antifungal Susceptibility Testing of Aspergillus Species. Journal of Clinical Microbiology, 2002, 40, 2876-2885.	1.8	59
215	Peripheral neuropathy in patients on long-term triazole antifungal therapy. Journal of Antimicrobial Chemotherapy, 2011, 66, 2136-2139.	1.3	59
216	The Efficacy of Crotalidae Polyvalent Immune Fab (Ovine) Antivenom Versus Placebo Plus Optional RescueÂTherapy on Recovery From Copperhead Snake Envenomation: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial. Annals of Emergency Medicine, 2017, 70, 233-244.e3.	0.3	59

#	Article	IF	Citations
217	Bioassay for serum itraconazole concentrations using hydroxyitraconazole standards. Antimicrobial Agents and Chemotherapy, 1994, 38, 1561-1566.	1.4	58
218	Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrobial Agents and Chemotherapy, 1997, 41, 2310-2311.	1.4	58
219	Invasive Aspergillosis as an Opportunistic Infection in Nonallografted Patients with Multiple Myeloma: A European Organization for Research and Treatment of Cancer. Clinical Infectious Diseases, 2000, 30, 41-46.	2.9	58
220	A Phase III Study of Recombinant Human Interferon Gamma to Prevent Opportunistic Infections in Advanced HIV Disease. AIDS Research and Human Retroviruses, 2001, 17, 789-797.	0.5	57
221	Susceptibility Testing of Aspergillus flavus : Inoculum Dependence with Itraconazole and Lack of Correlation between Susceptibility to Amphotericin B In Vitro and Outcome In Vivo. Antimicrobial Agents and Chemotherapy, 2001, 45, 1456-1462.	1.4	57
222	Antifungal susceptibility testing inAspergillusspp. according to EUCAST methodology. Medical Mycology, 2006, 44, 319-325.	0.3	57
223	In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. Journal of Antimicrobial Chemotherapy, 1998, 42, 91-94.	1.3	56
224	In Vitro Activities of Terbinafine against Aspergillus Species in Comparison with Those of Itraconazole and Amphotericin B. Antimicrobial Agents and Chemotherapy, 2001, 45, 1882-1885.	1.4	56
225	Insight into the genome of Aspergillus fumigatus: analysis of a 922kb region encompassing the nitrate assimilation gene cluster. Fungal Genetics and Biology, 2004, 41, 443-453.	0.9	55
226	Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. Journal of Antimicrobial Chemotherapy, 2008, 63, 161-166.	1.3	55
227	Emergence of Echinocandin Resistance Due to a Point Mutation in the fks1 Gene of Aspergillus fumigatus in a Patient with Chronic Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	55
228	The Management of Chronic Pulmonary Aspergillosis: The UK National Aspergillosis Centre Approach. Current Fungal Infection Reports, 2017, 11, 242-251.	0.9	55
229	Aspergillus DNA contamination in blood collection tubes. Diagnostic Microbiology and Infectious Disease, 2010, 67, 392-394.	0.8	54
230	TOO MANY MOULDY JOINTS â€“ MARIJUANA AND CHRONIC PULMONARY ASPERGILLOSIS. Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e2011005.	0.5	54
231	Burden of serious fungal infections in Spain. Clinical Microbiology and Infection, 2015, 21, 183-189.	2.8	54
232	The global distribution of actinomycetoma and eumycetoma. PLoS Neglected Tropical Diseases, 2020, 14, e0008397.	1.3	53
233	Dose Range Evaluation of Liposomal Nystatin and Comparisons with Amphotericin B and Amphotericin B Lipid Complex in Temporarily Neutropenic Mice Infected with an Isolate of Aspergillus fumigatus with Reduced Susceptibility to Amphotericin B. Antimicrobial Agents and Chemotherapy, 1999, 43, 2592-2599.	1.4	52
234	A study on Aspergillus species in houses of asthmatic patients from Sari City, Iran and a brief review of the health effects of exposure to indoor Aspergillus. Environmental Monitoring and Assessment, 2010, 168, 481-487.	1.3	52

#	Article	IF	Citations
235	The global impact of Aspergillus infection on COPD. BMC Pulmonary Medicine, 2020, 20, 241.	0.8	52
236	A global call for talaromycosis to be recognised as a neglected tropical disease. The Lancet Global Health, 2021, 9, e1618-e1622.	2.9	52
237	Efficacy of D0870 compared with those of itraconazole and amphotericin B in two murine models of invasive aspergillosis. Antimicrobial Agents and Chemotherapy, 1995, 39, 1809-1814.	1.4	51
238	EUCAST Technical Note on voriconazole. Clinical Microbiology and Infection, 2008, 14, 985-987.	2.8	51
239	Occurrence of azole-resistant species of Aspergillus in the UK environment. Journal of Global Antimicrobial Resistance, 2014, 2, 276-279.	0.9	51
240	Improvement of fungal disease identification and management: combined health systems and public health approaches. Lancet Infectious Diseases, The, 2017, 17, e412-e419.	4.6	51
241	Anti-Aspergillus Activities of the Respiratory Epithelium in Health and Disease. Journal of Fungi (Basel,) Tj ETQq1 1 0.784314 rgBT /Ov	1.5	51
242	Restriction endonuclease analysis of human and bovine group B streptococci for epidemiologic study. Journal of Clinical Microbiology, 1989, 27, 1352-1356.	1.8	51
243	Efficacy of Antifungal Therapy in a Nonneutropenic Murine Model of Zygomycosis. Antimicrobial Agents and Chemotherapy, 2002, 46, 1953-1959.	1.4	50
244	Correlation betweenin vitrogrowth rate andin vivovirulence inAspergillus fumigatus. Medical Mycology, 2005, 43, 397-401.	0.3	50
245	Chronic mucocutaneous candidiasis and oesophageal cancer. Medical Mycology, 2008, 46, 85-91.	0.3	50
246	Statistical Analyses of Correlation between Fluconazole MICs for Candida spp. Assessed by Standard Methods Set Forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). Journal of Clinical Microbiology, 2007, 45, 109-111.	1.8	49
247	Invasive aspergillosis in immunocompromised patients. Current Opinion in Infectious Diseases, 1994, 7, 456-462.	1.3	48
248	Impaired dendritic cell maturation and cytokine production in patients with chronic mucocutanous candidiasis with or without APECED. Clinical and Experimental Immunology, 2008, 154, 406-414.	1.1	48
249	Pulmonary aspergillosis: an alternative diagnosis to lung cancer after positive [18F]FDG positron emission tomography. Thorax, 2011, 66, 638-640.	2.7	48
250	The ambitious '95-95 by 2025' roadmap for the diagnosis and management of fungal diseases. Thorax, 2015, 70, 613-614.	2.7	48
251	Stress-Induced Changes in the Lipid Microenvironment of Î²-(1,3)- <scp>d</scp> -Glucan Synthase Cause Clinically Important Echinocandin Resistance in Aspergillus fumigatus. MBio, 2019, 10, .	1.8	48
252	Generic substitution of itraconazole resulting in sub-therapeutic levels and resistance. International Journal of Antimicrobial Agents, 2007, 30, 93-94.	1.1	47

#	Article	IF	Citations
253	Voriconazole-induced photosensitivity: photobiological assessment of a case series of 12 patients. British Journal of Dermatology, 2013, 168, 179-185.	1.4	47
254	Cryptococcal meningitis: A neglected NTD?. PLoS Neglected Tropical Diseases, 2017, 11, e0005575.	1.3	47
255	Polarized Growth of Fungal Hyphae Is Defined by an Alkaline pH Gradient. Fungal Genetics and Biology, 1996, 20, 289-298.	0.9	46
256	Efficacy and safety of nebulised amphotericin B (NAB) in severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA). Journal of Asthma, 2015, 52, 289-295.	0.9	45
257	Calling upon all public health mycologists. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 923-924.	1.3	45
258	Lack of vessel wall elastolysis in human invasive pulmonary aspergillosis. Infection and Immunity, 1992, 60, 5153-5156.	1.0	45
259	In vitro activity of D0870 compared with those of other azoles against fluconazole-resistant Candida spp. Antimicrobial Agents and Chemotherapy, 1995, 39, 868-871.	1.4	44
260	Comparison of two fluorescent whiteners, Calcofluor and Blankophor, for the detection of fungal elements in clinical specimens in the diagnostic laboratory. Clinical Microbiology and Infection, 2006, 12, 181-184.	2.8	44
261	Genomic analysis of allergen genes inAspergillusspp.: the relevance of genomics to everyday research. Medical Mycology, 2007, 45, 17-26.	0.3	44
262	Genetic variability of innate immunity impacts human susceptibility to fungal diseases. International Journal of Infectious Diseases, 2010, 14, e460-e468.	1.5	44
263	Histoplasma capsulatum antigen detection tests as an essential diagnostic tool for patients with advanced HIV disease in low and middle income countries: A systematic review of diagnostic accuracy studies. PLoS Neglected Tropical Diseases, 2018, 12, e0006802.	1.3	44
264	Major variations in Aspergillus fumigatus arising within aspergillomas in chronic pulmonary aspergillosis. Mycoses, 2013, 56, 434-441.	1.8	43
265	Editorial Commentary: Voriconazole Resistance in Aspergillus fumigatus: Should We Be Concerned?. Clinical Infectious Diseases, 2013, 57, 521-523.	2.9	43
266	Serious fungal infections in Pakistan. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 949-956.	1.3	43
267	Burden of fungal asthma in Africa: A systematic review and meta-analysis. PLoS ONE, 2019, 14, e0216568.	1.1	43
268	Successful Treatment of Sinusitis Caused by Cunninghamella bertholletiae. Clinical Infectious Diseases, 1994, 19, 313-316.	2.9	42
269	Amphotericin B resistance testing of Candida spp.: a comparison of methods. Journal of Antimicrobial Chemotherapy, 1997, 40, 109-112.	1.3	42
270	Whole genome comparison of theA. fumigatusfamily. Medical Mycology, 2006, 44, 3-7.	0.3	42

#	Article	IF	Citations
271	Homogenisation of cystic fibrosis sputum by sonication â€" An essential step for Aspergillus PCR. Journal of Microbiological Methods, 2011, 85, 75-81.	0.7	42
272	Azole Antifungal Resistance Today: Focus on Aspergillus. Current Infectious Disease Reports, 2011, 13, 485-491.	1.3	42
273	Validity and Reliability of the St. George's Respiratory Questionnaire in Assessing Health Status in Patients With Chronic Pulmonary Aspergillosis. Chest, 2013, 144, 623-631.	0.4	42
274	Estimated burden of fungal infections in Germany. Mycoses, 2015, 58, 22-28.	1.8	42
275	Skull base osteitis following fungal sinusitis. Journal of Laryngology and Otology, 1998, 112, 92-97.	0.4	41
276	In Vitro Synergistic Interaction between Amphotericin B and Pentamidine against Scedosporium prolificans. Antimicrobial Agents and Chemotherapy, 2002, 46, 3323-3326.	1.4	41
277	Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus and Candida. Journal of Antimicrobial Chemotherapy, 2004, 53, 743-749.	1.3	41
278	Genomics of Aspergillus fumigatus. Revista Iberoamericana De Micologia, 2005, 22, 223-228.	0.4	41
279	Derivation of an In Vivo Drug Exposure Breakpoint for Flucytosine against Candida albicans and Impact of the MIC, Growth Rate, and Resistance Genotype on the Antifungal Effect. Antimicrobial Agents and Chemotherapy, 2006, 50, 3680-3688.	1.4	41
280	Voriconazole plasma monitoring. Archives of Disease in Childhood, 2008, 93, 578-581.	1.0	40
281	Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort. European Journal of Clinical Microbiology and Infectious Diseases, 2010, 29, 1387-1394.	1.3	40
282	Republished: The clinical spectrum of pulmonary aspergillosis. Postgraduate Medical Journal, 2015, 91, 403-410.	0.9	40
283	Lung colonization by Aspergillus fumigatus is controlled by ZNF77. Nature Communications, 2018, 9, 3835.	5.8	40
284	The global burden of chromoblastomycosis. PLoS Neglected Tropical Diseases, 2021, 15, e0009611.	1.3	40
285	Tuberculosis/cryptococcosis co-infection in China between 1965 and 2016. Emerging Microbes and Infections, 2017, 6, 1-7.	3.0	39
286	The case for paracoccidioidomycosis to be accepted as a neglected tropical (fungal) disease. PLoS Neglected Tropical Diseases, 2019, 13, e0007195.	1.3	39
287	Clinical implications of interferonâ€Î³ genetic and epigenetic variants. Immunology, 2014, 143, 499-511.	2.0	38
288	The Diagnosis of Fungal Neglected Tropical Diseases (Fungal NTDs) and the Role of Investigation and Laboratory Tests: An Expert Consensus Report. Tropical Medicine and Infectious Disease, 2019, 4, 122.	0.9	38

#	Article	IF	Citations
289	Mitochondrial Complex I Is a Global Regulator of Secondary Metabolism, Virulence and Azole Sensitivity in Fungi. PLoS ONE, 2016, 11, e0158724.	1.1	38
290	, a multi-resistant fungus, from a U.K. AIDS patient. Journal of Infection, 1995, 30, 153-155.	1.7	37
291	Identification of novel genes conferring altered azole susceptibility in Aspergillus fumigatus. FEMS Microbiology Letters, 2012, 332, 10-19.	0.7	37
292	Frequency, diagnosis and management of fungal respiratory infections. Current Opinion in Pulmonary Medicine, 2013, 19, 259-265.	1.2	37
293	Genetic susceptibility to allergic bronchopulmonary aspergillosis in asthma: a genetic association study. Allergy, Asthma and Clinical Immunology, 2016, 12, 47.	0.9	37
294	Efficacy of oral saperconazole in systemic murine aspergillosis. Medical Mycology, 1995, 33, 311-317.	0.3	36
295	Serious fungal infections in Egypt. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 971-974.	1.3	36
296	Evaluation of LDBio Aspergillus ICT Lateral Flow Assay for IgG and IgM Antibody Detection in Chronic Pulmonary Aspergillosis. Journal of Clinical Microbiology, 2019, 57, .	1.8	36
297	Endocarditis Due to Trichosporon beigelii: In Vitro Susceptibility of Isolates and Review. Clinical Infectious Diseases, 1991, 13, 383-386.	2.9	35
298	Effect of Neutropenia and Treatment Delay on the Response to Antifungal Agents in Experimental Disseminated Candidiasis. Antimicrobial Agents and Chemotherapy, 2007, 51, 285-295.	1.4	35
299	Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus. International Journal of Antimicrobial Agents, 2010, 35, 146-151.	1.1	35
300	Serious fungal infections in Canada. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 987-992.	1.3	35
301	Genetic susceptibility to severe asthma with fungal sensitization. International Journal of Immunogenetics, 2017, 44, 93-106.	0.8	35
302	Mapping histoplasmosis in South East Asia â€“ implications for diagnosis in AIDS. Emerging Microbes and Infections, 2019, 8, 1139-1145.	3.0	35
303	Fungal infection of the diabetic foot: two distinct syndromes. Diabetic Medicine, 2001, 18, 567-572.	1.2	34
304	Aspergillosis in â€œNonimmunocompromisedâ€•Critically Ill Patients. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 580-581.	2.5	34
305	Burden of fungal infections in Qatar. Mycoses, 2015, 58, 51-57.	1.8	34
306	Burden of serious fungal infections in Mexico. Mycoses, 2015, 58, 34-44.	1.8	34

#	Article	IF	Citations
307	Pulmonary Aspergillosis in Patients with Suspected Ventilator-associated Pneumonia in UK ICUs. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1125-1132.	2.5	34
308	Antifungal drug resistance: an update. European Journal of Hospital Pharmacy, 2022, 29, 109-112.	0.5	34
309	Antifungal Susceptibility Testing of Fluconazole by Flow Cytometry Correlates with Clinical Outcome. Journal of Clinical Microbiology, 2001, 39, 2458-2462.	1.8	33
310	In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis. Journal of Antimicrobial Chemotherapy, 2002, 50, 1071-1074.	1.3	33
311	Comparison of extracellular phospholipase activities in clinical and environmentalAspergillus fumigatusisolates. Medical Mycology, 2004, 42, 81-86.	0.3	33
312	Burden of serious fungal infections in Tanzania. Mycoses, 2015, 58, 70-79.	1.8	33
313	HIV-Associated Cryptococcal Disease in Resource-Limited Settings: A Case for â€œPrevention Is Better Than Cureâ€?. Journal of Fungi (Basel, Switzerland), 2017, 3, 67.	1.5	33
314	Standards of care for patients with invasive fungal infections within the United Kingdom: A national audit. Journal of Infection, 2009, 58, 145-153.	1.7	32
315	Mannoseâ€binding lectin genotype and serum levels in patients with chronic and allergic pulmonary aspergillosis. International Journal of Immunogenetics, 2012, 39, 224-232.	0.8	32
316	Reduced expression of TLR3, TLR10 and TREM1 by human macrophages in Chronic cavitary pulmonary aspergillosis, and novel associations of VEGFA, DENND1B and PLAT. Clinical Microbiology and Infection, 2014, 20, O960-O968.	2.8	32
317	Death Due to Carbamazepine Self-poisoning: Remedies Reviewed. Human Toxicology, 1985, 4, 255-260.	0.9	31
318	Neuralgic amyotrophy due to parvovirus infection.. Journal of Neurology, Neurosurgery and Psychiatry, 1987, 50, 641-642.	0.9	31
319	Uncommon invasive mycoses in AIDS. Aids, 1995, 9, 411-420.	1.0	31
320	Aspergillus fumigatuscatalases: cloning of anAspergillus nidulanscatalase B homologue and evidence for at least three catalases. FEMS Immunology and Medical Microbiology, 1999, 23, 125-133.	2.7	31
321	Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis. Journal of Antimicrobial Chemotherapy, 2005, 56, 590-593.	1.3	31
322	What theAspergillusgenomes have told us. Medical Mycology, 2005, 43, 3-5.	0.3	31
323	Receiver operating characteristic curve analysis of four Aspergillus -specific IgG assays for the diagnosis of chronic pulmonary aspergillosis. Diagnostic Microbiology and Infectious Disease, 2018, 91, 47-51.	0.8	31
324	Risk-Based Estimate of Human Fungal Disease Burden, China. Emerging Infectious Diseases, 2020, 26, 2137-2147.	2.0	31

#	Article	IF	Citations
325	An investigation of antifungal stewardship programmes in England. Journal of Medical Microbiology, 2017, 66, 1581-1589.	0.7	31
326	Neisseria lactamica Meningitis Following Skull Trauma. Clinical Infectious Diseases, 1991, 13, 216-218.	2.9	30
327	Comparison of D0870, a new triazole antifungal agent, to fluconazole for inhibition of Candida albicans cytochrome P-450 by using in vitro assays. Antimicrobial Agents and Chemotherapy, 1996, 40, 1382-1386.	1.4	30
328	Invasive aspergillosis: current and future challenges in diagnosis and therapy. Clinical Microbiology and Infection, 2004, 10, 2-4.	2.8	30
329	A prominent role for the IL1 pathway and IL15 in susceptibility to chronic cavitary pulmonary aspergillosis. Clinical Microbiology and Infection, 2014, 20, O480-O488.	2.8	30
330	Burden of fungal infections in Senegal. Mycoses, 2015, 58, 63-69.	1.8	30
331	D-mannitol in cerebrospinal fluid of patients with AIDS and cryptococcal meningitis. Journal of Clinical Microbiology, 1996, 34, 218-221.	1.8	30
332	DNA typing of epidemiologically-related isolates ofAspergillus fumigatus. Epidemiology and Infection, 1995, 114, 161-168.	1.0	29
333	Detection ofAspergillusin lung and other tissue samples using the MycAssay Aspergillus real-time PCR kit. Canadian Journal of Microbiology, 2011, 57, 765-768.	0.8	29
334	The Performance of Real-Time PCR, Galactomannan, and Fungal Culture in the Diagnosis of Invasive Aspergillosis in Ventilated Patients with Chronic Obstructive Pulmonary Disease (COPD). Mycopathologia, 2012, 174, 163-169.	1.3	29
335	Burden of serious fungal infections in Nepal. Mycoses, 2015, 58, 45-50.	1.8	29
336	Impact of liposomal amphotericin B therapy on chronic pulmonary aspergillosis. Journal of Infection, 2016, 73, 485-495.	1.7	29
337	Burden of Fungal Infections in Colombia. Journal of Fungi (Basel, Switzerland), 2018, 4, 41.	1.5	29
338	Comparison of Guizotia abyssinica seed extract (birdseed) agar with conventional media for selective identification of Cryptococcus neoformans in patients with acquired immunodeficiency syndrome. Journal of Clinical Microbiology, 1990, 28, 2565-2567.	1.8	29
339	Risk factors associated with respiratory infectious disease-related presenteeism: a rapid review. BMC Public Health, 2021, 21, 1955.	1.2	29
340	In-vitro activity of the new triazole D0870 compared with amphotericin B and itraconazole against Aspergilus spp.. Journal of Antimicrobial Chemotherapy, 1993, 32, 831-836.	1.3	28
341	Aspergillosis and the role of mucins in cystic fibrosis. Pediatric Pulmonology, 2017, 52, 548-555.	1.0	28
342	Elevated Aspergillus-specific antibody levels among HIV infected Ugandans with pulmonary tuberculosis. BMC Pulmonary Medicine, 2017, 17, 149.	0.8	28

#	Article	IF	Citations
343	The Burden of Serious Fungal Infections in Cameroon. Journal of Fungi (Basel, Switzerland), 2018, 4, 44.	1.5	28
344	Essential in vitro diagnostics for advanced HIV and serious fungal diseases: international expertsâ€™ consensus recommendations. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1581-1584.	1.3	28
345	Chronic Pulmonary Histoplasmosisâ€"A Scoping Literature Review. Open Forum Infectious Diseases, 2020, 7, ofaa119.	0.4	28
346	Chronic Pulmonary Aspergillosis: Notes for a Clinician in a Resource-Limited Setting Where There Is No Mycologist. Journal of Fungi (Basel, Switzerland), 2020, 6, 75.	1.5	28
347	Burden of fungal disease in Ireland. Journal of Medical Microbiology, 2015, 64, 423-426.	0.7	27
348	Bone and joint infections caused by mucormycetes: A challenging osteoarticular mycosis of the twenty-first century. Medical Mycology, 2017, 55, myw136.	0.3	27
349	Serious fungal infections in Thailand. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 931-935.	1.3	27
350	Effect of involved Aspergillus species on galactomannan in bronchoalveolar lavage of patients with invasive aspergillosis. Journal of Medical Microbiology, 2017, 66, 898-904.	0.7	27
351	Species differentiation by internally transcribed spacer PCR and HhaI digestion of fluconazole-resistant Candida krusei, Candida inconspicua, and Candida norvegensis strains. Journal of Clinical Microbiology, 1997, 35, 1036-1039.	1.8	27
352	Aspergillosis: diagnosis and treatment. International Journal of Antimicrobial Agents, 1996, 6, 161-168.	1.1	26
353	Inhibition and interaction of cytochrome P450 ofCandida kruseiwith azole antifungal drugs. Medical Mycology, 1997, 35, 19-25.	0.3	26
354	Burden of serious fungal infections in Guatemala. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 965-969.	1.3	26
355	Recovery from serious fungal infections should be realisable for everyone. Lancet Infectious Diseases, The, 2017, 17, 1111-1113.	4.6	26
356	Future Research Priorities in Fungal Resistance. Journal of Infectious Diseases, 2017, 216, S484-S492.	1.9	26
357	Getting Histoplasmosis on the Map of International Recommendations for Patients with Advanced HIV Disease. Journal of Fungi (Basel, Switzerland), 2019, 5, 80.	1.5	26
358	Estimated burden of fungal infections in Kenya. Journal of Infection in Developing Countries, 2016, 10, 777-784.	0.5	26
359	Acute pulmonary aspergillosis in immunocompetent subjects after exposure to bark chippings. Scandinavian Journal of Infectious Diseases, 2006, 38, 945-949.	1.5	25
360	Development of chronic pulmonary aspergillosis in adult asthmatics with ABPA. Respiratory Medicine, 2015, 109, 1509-1515.	1.3	25

#	Article	IF	Citations
361	Aspergillusarthritis: analysis of clinical manifestations, diagnosis, and treatment of 31 reported cases. Medical Mycology, 2016, 55, myw077.	0.3	25
362	The Burden of Fungal Infections in Ethiopia. Journal of Fungi (Basel, Switzerland), 2019, 5, 109.	1.5	25
363	Unilateral wheeze caused by pseudomembranous aspergillus tracheobronchitis in the immunocompromised patient.. Thorax, 1993, 48, 1285-1287.	2.7	24
364	Cryptococcal meningitis in the immunocompromised host: intracranial hypertension and other complications. Mycopathologia, 1999, 146, 1-8.	1.3	24
365	Antifungal activity of human polymorphonuclear and mononuclear phagocytes against non-fumigatus Aspergillus species. Phagozytose-Aktivitat humaner polymorphonuklearer und monouklearer Phagozyten gegen Nicht-fumigatus-Aspergillus-Arten. Mycoses, 2003, 46, 77-83.	1.8	24
366	Stevens et al. (2003;â€‰37[Suppl 3]:S225â€“64). Clinical Infectious Diseases, 2004, 38, 158-158.	2.9	24
367	EndogenousCandidaendophthalmitis and osteomyelitis associated with CARD9 deficiency. BMJ Case Reports, 2016, 2016, bcr2015214117.	0.2	24
368	Burden of fungal infections in Algeria. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 999-1004.	1.3	24
369	The Diagnostic Laboratory Hub: A New Health Care System Reveals the Incidence and Mortality of Tuberculosis, Histoplasmosis, and Cryptococcosis of PWH in Guatemala. Open Forum Infectious Diseases, 2020, 7, ofz534.	0.4	24
370	Mycetoma in Uganda: A neglected tropical disease. PLoS Neglected Tropical Diseases, 2020, 14, e0008240.	1.3	24
371	Empiric amphotericin B therapy: the need for a reappraisal. Blood Reviews, 1993, 7, 208-214.	2.8	23
372	An aspergilloma caused byAspergillus flavus. Medical Mycology, 2008, 46, 275-278.	0.3	23
373	Burden of serious fungal infections in Bangladesh. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 993-997.	1.3	23
374	Comparative performance of Aspergillus galactomannan ELISA and PCR in sputum from patients with ABPA and CPA. Journal of Microbiological Methods, 2017, 140, 32-39.	0.7	23
375	Estimated Burden of Serious Fungal Infections in Mozambique. Journal of Fungi (Basel, Switzerland), 2018, 4, 75.	1.5	23
376	Comparative performance of the laboratory assays used by a Diagnostic Laboratory Hub for opportunistic infections in people living with HIV. Aids, 2020, 34, 1625-1632.	1.0	23
377	Burden of serious fungal infections in the Netherlands. Mycoses, 2020, 63, 625-631.	1.8	23
378	Analysis of UK Sera for Aflatoxin by Enzyme-linked Immunosorbent Assay. Human Toxicology, 1988, 7, 353-356.	0.9	22

#	Article	IF	Citations
379	Rapid genotyping ofEscherichia coli O157 isolates by random amplification of polymorphic DNA. European Journal of Clinical Microbiology and Infectious Diseases, 1996, 15, 297-302.	1.3	22
380	SUCCESSFUL TREATMENT OF ASPERGILLUS BRAIN ABSCESS IN A CHILD WITH ACUTE LYMPHOBLASTIC LEUKEMIA. Pediatric Hematology and Oncology, 2000, 17, 497-504.	0.3	22
381	Pattern recognition receptor expression is not impaired in patients with chronic mucocutanous candidiasis with or without autoimmune polyendocrinopathy candidiasis ectodermal dystrophy. Clinical and Experimental Immunology, 2009, 156, 40-51.	1.1	22
382	Isolation, identification and susceptibility of Pyrenochaeta romeroi in a case of eumycetoma of the foot in the UK. International Journal of Antimicrobial Agents, 2009, 34, 613-614.	1.1	22
383	Development and Evaluation of a Calibrator Material for Nucleic Acid-Based Assays for Diagnosing Aspergillosis. Journal of Clinical Microbiology, 2013, 51, 2403-2405.	1.8	22
384	Electrophilic, Activation-Free Fluorogenic Reagent for Labeling Bioactive Amines. Bioconjugate Chemistry, 2016, 27, 1430-1434.	1.8	22
385	Estimated Burden of Serious Fungal Infections in Ghana. Journal of Fungi (Basel, Switzerland), 2019, 5, 38.	1.5	22
386	The role of antifungals in the management of patients with severe asthma. Clinical and Translational Allergy, 2020, 10, 46.	1.4	22
387	A Rapid Screening Program for Histoplasmosis, Tuberculosis, and Cryptococcosis Reduces Mortality in HIV Patients from Guatemala. Journal of Fungi (Basel, Switzerland), 2021, 7, 268.	1.5	22
388	Diagnostic and Therapeutic Strategies for Invasive Aspergillosis. Seminars in Respiratory and Critical Care Medicine, 1997, 18, 203-215.	0.8	21
389	In Vivo Activity of Amphotericin B Lipid Complex in Immunocompromised Mice against Fluconazole-Resistant or Fluconazole-Susceptible Candida tropicalis. Antimicrobial Agents and Chemotherapy, 2000, 44, 2664-2671.	1.4	21
390	Treatment of Absidia corymbifera infection in mice with amphotericin B and itraconazole. Journal of Antimicrobial Chemotherapy, 2001, 48, 583-586.	1.3	21
391	Optimization of the Dosage of Flucytosine in Combination with Amphotericin B for Disseminated Candidiasis: a Pharmacodynamic Rationale for Reduced Dosing. Antimicrobial Agents and Chemotherapy, 2007, 51, 3760-3762.	1.4	21
392	What is the importance of classifyingAspergillusdisease in cystic fibrosis patients?. Expert Review of Respiratory Medicine, 2014, 8, 389-392.	1.0	21
393	Burden of serious fungal infections in Belgium. Mycoses, 2015, 58, 1-5.	1.8	21
394	Innate and Adaptive Immune Defects in Chronic Pulmonary Aspergillosis. Journal of Fungi (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 1	1.5	21
395	Aspergillus wound infection following laparostomy. Journal of Infection, 1996, 33, 119-121.	1.7	20
396	Therapy of deep fungal infection in haematological malignancy. Working Party of the British Society for Antimicrobial Chemotherapy. Journal of Antimicrobial Chemotherapy, 1997, 40, 779-788.	1.3	20

#	Article	IF	Citations
397	Advances against Aspergillosis. Clinical Infectious Diseases, 2003, 37, S155-S156.	2.9	20
398	Tremor: a newly described adverse event with long-term itraconazole therapy. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 327-329.	0.9	20
399	Antifungal resistance: more research needed. Lancet, The, 2014, 384, 1427.	6.3	20
400	Improved Detection of Invasive Pulmonary Aspergillosis Arising during Leukemia Treatment Using a Panel of Host Response Proteins and Fungal Antigens. PLoS ONE, 2015, 10, e0143165.	1.1	20
401	Cryptococcal Antigenemia in Nigerian Patients With Advanced Human Immunodeficiency Virus: Influence of Antiretroviral Therapy Adherence. Open Forum Infectious Diseases, 2016, 3, ofw055.	0.4	20
402	Inducible Cell Fusion Permits Use of Competitive Fitness Profiling in the Human Pathogenic Fungus Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	20
403	Non-infectious status indicated by detectable IgG antibody to SARS-CoV-2. British Dental Journal, 2020, 229, 521-524.	0.3	20
404	Evaluation of the LDBio Aspergillus ICT lateral flow assay for serodiagnosis of allergic bronchopulmonary aspergillosis. PLoS ONE, 2020, 15, e0238855.	1.1	20
405	Oral Itraconazole Therapy of Cryptococcal Meningitis and Cryptococcosis in Patients with AIDS. , 1990, , 305-324.		20
406	Pulmonary and Extrapulmonary Manifestations of Fungal Infections Misdiagnosed as Tuberculosis: The Need for Prompt Diagnosis and Management. Journal of Fungi (Basel, Switzerland), 2022, 8, 460.	1.5	20
407	Infant with two relapses of Group B streptococcal sepsis documented by DNA restriction enzyme analysis. Pediatric Infectious Disease Journal, 1988, 7, 729-732.	1.1	19
408	Invasive pulmonary aspergillosis transformed into fatal mucous impaction by immune reconstitution in an AIDS patient. European Journal of Clinical Microbiology and Infectious Diseases, 2005, 24, 628-633.	1.3	19
409	The burden of fungal disease in Denmark. Mycoses, 2015, 58, 15-21.	1.8	19
410	Burden of serious fungal infections in the Dominican Republic. Journal of Infection and Public Health, 2016, 9, 7-12.	1.9	19
411	Serious fungal infections in the Philippines. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 937-941.	1.3	19
412	Burden of fungal infections in Iran. Journal of Infection in Developing Countries, 2018, 12, 910-918.	0.5	19
413	Measurement of aflatoxin in Nigerian sera by enzyme-linked immunosorbent assay. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1988, 82, 169-171.	0.7	18
414	TRANSMISSION OF EPSTEIN-BARR VIRUS BY A TRANSPLANTED KIDNEY, WITH ACTIVATION BY OKT3 ANTIBODY. Transplantation, 1989, 48, 141-144.	0.5	18

#	Article	IF	Citations
415	Aflatoxin and outcome from acute lower respiratory infection in children in The Philippines. Annals of Tropical Paediatrics, 1995, 15, 209-216.	1.0	18
416	Surface Response Modeling to Examine the Combination of Amphotericin B Deoxycholate and 5â€Fluorocytosine for Treatment of Invasive Candidiasis. Journal of Infectious Diseases, 2005, 192, 673-680.	1.9	18
417	Relative reactivity ofAspergillusallergens used in serological tests. Medical Mycology, 2006, 44, 23-28.	0.3	18
418	Aspergillus fumigatus Bronchopneumonia in a Hellenic Shepherd Dog. Journal of the American Animal Hospital Association, 2011, 47, e13-e18.	0.5	18
419	Frequency of Pneumocystis jirovecii in sputum from HIV and TB patients in Namibia. Journal of Infection in Developing Countries, 2014, 8, 349-357.	0.5	18
420	Burden of Serious Fungal Infections in Jordan. Journal of Fungi (Basel, Switzerland), 2018, 4, 15.	1.5	18
421	Burden of Serious Fungal Infections in Argentina. Journal of Fungi (Basel, Switzerland), 2018, 4, 51.	1.5	18
422	Siemens Immulite Aspergillus-specific IgG assay for chronic pulmonary aspergillosis diagnosis. Medical Mycology, 2019, 57, 300-307.	0.3	18
423	Bridging the knowledge gap on mycoses in Africa: Setting up a Panâ€African Mycology Working Group. Mycoses, 2020, 63, 244-249.	1.8	18
424	Ending deaths from HIV-related cryptococcal meningitis by 2030. Lancet Infectious Diseases, The, 2021, 21, 16-18.	4.6	18
425	One Health aspects & priority roadmap for fungal diseases : A mini-review. Indian Journal of Medical Research, 2021, 153, 311.	0.4	18
426	In vitro activity of saperconazole (R66 905) compared with amphotericin B and itraconazole againstAspergillus species. European Journal of Clinical Microbiology and Infectious Diseases, 1990, 9, 693-697.	1.3	17
427	Control of invasive pulmonary aspergillosis with oral itraconazole in a bone marrow transplant patient. Journal of Infection, 1992, 24, 73-79.	1.7	17
428	Antifungal drug susceptibility testing: Working Party of the British Society for Antimicrobial Chemotherapy. Journal of Antimicrobial Chemotherapy, 1995, 36, 899-909.	1.3	17
429	The challenge of invasive aspergillosis: Increasing numbers in diverse patient groups. International Journal of Infectious Diseases, 1997, 2, 61-63.	1.5	17
430	Aspergillus Genomes and the Aspergillus Cloud. Nucleic Acids Research, 2009, 37, D509-D514.	6.5	17
431	Allergic bronchopulmonary mycosis due to Alternaria: Case report and review. Medical Mycology Case Reports, 2012, 1, 20-23.	0.7	17
432	Burden of serious fungal infections in the Czech Republic. Mycoses, 2015, 58, 6-14.	1.8	17

#	Article	IF	Citations
433	Elevated Levels of the Neutrophil Chemoattractant Proâ€“Platelet Basic Protein in Macrophages From Individuals With Chronic and Allergic Aspergillosis. Journal of Infectious Diseases, 2015, 211, 651-660.	1.9	17
434	The Burden of Fungal Diseases in Romania. Journal of Fungi (Basel, Switzerland), 2018, 4, 31.	1.5	17
435	Mutations in EEA1 are associated with allergic bronchopulmonary aspergillosis and affect phagocytosis of Aspergillus fumigatus by human macrophages. PLoS ONE, 2018, 13, e0185706.	1.1	17
436	Prior subclinical histoplasmosis revealed in Nigeria using histoplasmin skin testing. PLoS ONE, 2018, 13, e0196224.	1.1	17
437	An ELISA method for the rapid and simple determination of aflatoxin in human serum. Food Additives and Contaminants, 1988, 5, 609-619.	2.0	16
438	Response to pneumococcal polysaccharide vaccination in patients with chronic and allergic aspergillosis. Vaccine, 2015, 33, 7271-7275.	1.7	16
439	The antiseptic Miramistin: a review of its comparative in vitro and clinical activity. FEMS Microbiology Reviews, 2020, 44, 399-417.	3.9	16
440	Clinical outcomes of patients with chronic pulmonary aspergillosis managed surgically. European Journal of Cardio-thoracic Surgery, 2020, 58, 997-1003.	0.6	16
441	Impact of the COVID-19 pandemic on HIV care in Guatemala. International Journal of Infectious Diseases, 2021, 108, 422-427.	1.5	16
442	Evaluation of knowledge and awareness of invasive fungal infections amongst resident doctors in Nigeria. Pan African Medical Journal, 2020, 36, 297.	0.3	16
443	Quantitative preservation of viability ofAspergillus fumigatus. Medical Mycology, 1992, 30, 485-488.	0.3	15
444	Molecular Typing of Aspergillus terreus by Random Amplification of Polymorphic DNA. European Journal of Clinical Microbiology and Infectious Diseases, 1999, 18, 838-841.	1.3	15
445	Using aCGH to study intraspecific genetic variability in two pathogenic molds,Aspergillus fumigatusandAspergillus flavus. Medical Mycology, 2009, 47, S34-S41.	0.3	15
446	Aflatoxin and Ochratoxin Production by Aspergillus Species Under Ex Vivo Conditions. Mycopathologia, 2009, 168, 185-191.	1.3	15
447	Long-Term Stability at â^'20Â°C of Aspergillus Galactomannan in Serum and Bronchoalveolar Lavage Specimens. Journal of Clinical Microbiology, 2014, 52, 2108-2111.	1.8	15
448	Burden of serious fungal infections in Trinidad and Tobago. Mycoses, 2015, 58, 80-84.	1.8	15
449	Burden of serious fungal infections in Ukraine. Mycoses, 2015, 58, 94-100.	1.8	15
450	Characterisation of fatigue and its substantial impact on health status in a large cohort of patients with chronic pulmonary aspergillosis (CPA). Respiratory Medicine, 2016, 114, 117-122.	1.3	15

#	Article	IF	Citations
451	Microbial yield from physiotherapy assisted sputum production in respiratory outpatients. BMC Pulmonary Medicine, 2016, 16, 23.	0.8	15
452	Serious fungal infections in Chile. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 983-986.	1.3	15
453	Chronic fibrosing pulmonary aspergillosis: a cause of â€˜destroyed lungâ€™ syndrome. Infectious Diseases, 2017, 49, 296-301.	1.4	15
454	Assessment of posaconazole salvage therapy in chronic pulmonary aspergillosis using predefined response criteria. International Journal of Antimicrobial Agents, 2018, 52, 258-264.	1.1	15
455	Prospective study of the serum Aspergillus-specific IgG, IgA and IgM assays for chronic pulmonary aspergillosis diagnosis. BMC Infectious Diseases, 2019, 19, 694.	1.3	15
456	A prospective longitudinal study of chronic pulmonary aspergillosis in pulmonary tuberculosis in Indonesia (APICAL). Thorax, 2022, 77, 821-828.	2.7	15
457	High incidence of antifungal drug resistance in Candida tropicalis. International Journal of Antimicrobial Agents, 1996, 7, 241-245.	1.1	14
458	Pulmonary Aspergillosis in a Patient with Chronic Granulomatous Disease: Confirmation by Polymerase Chain Reaction and Serological Tests, and Successful Treatment with Voriconazole. European Journal of Clinical Microbiology and Infectious Diseases, 2003, 22, 681-685.	1.3	14
459	Comparison of 2 Studies of Treatment of Invasive Aspergillosis. Clinical Infectious Diseases, 2007, 45, 1106-1108.	2.9	14
460	Burden of serious fungal diseases in Hungary. Mycoses, 2015, 58, 29-33.	1.8	14
461	Serious fungal infections in Korea. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 957-963.	1.3	14
462	F508del CFTR gene mutation in patients with allergic bronchopulmonary aspergillosis. Journal of Asthma, 2018, 55, 837-843.	0.9	14
463	Diagnosis and Management of Pneumocystis Pneumonia in Resource-poor Settings. Journal of Health Care for the Poor and Underserved, 2018, 29, 107-158.	0.4	14
464	Estimated Burden of Serious Fungal Infections in Malawi. Journal of Fungi (Basel, Switzerland), 2018, 4, 61.	1.5	14
465	Estimation of the Burden of Serious Human Fungal Infections in Malaysia. Journal of Fungi (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock	1.5	14
466	The validity, reliability and minimal clinically important difference of the patient specific functional scale in snake envenomation. PLoS ONE, 2019, 14, e0213077.	1.1	14
467	Diagnostic Aspects of Chronic Pulmonary Aspergillosis: Present and New Directions. Current Fungal Infection Reports, 2019, 13, 292-300.	0.9	14
468	Evaluation and comparison of automated and manual ELISA for diagnosis of chronic pulmonary aspergillosis (CPA) in Indonesia. Diagnostic Microbiology and Infectious Disease, 2020, 98, 115124.	0.8	14

#	Article	IF	Citations
469	Chronic Pulmonary Aspergillosis Situation among Post Tuberculosis Patients in Vietnam: An Observational Study. Journal of Fungi (Basel, Switzerland), 2021, 7, 532.	1.5	14
470	Characterisation of Aspergillus fumigatus Endocytic Trafficking within Airway Epithelial Cells Using High-Resolution Automated Quantitative Confocal Microscopy. Journal of Fungi (Basel, Switzerland), 2021, 7, 454.	1.5	14
471	Cryptococcal and Histoplasma Antigen Screening Among People With Human Immunodeficiency Virus in Ghana and Comparative Analysis of OIDx Histoplasma Lateral Flow Assay and IMMY Histoplasma Enzyme Immunoassay. Open Forum Infectious Diseases, 2022, 9, .	0.4	14
472	Eradication of Low-Level Methicillin-Resistant Staphylococcus aureus Skin Colonization with Topical Mupirocin. Infection Control and Hospital Epidemiology, 1988, 9, 261-263.	1.0	13
473	Estimated burden of serious human fungal diseases in Turkey. Mycoses, 2019, 62, 22-31.	1.8	13
474	Incidence of Histoplasmosis in a Cohort of People with HIV: From Estimations to Reality. Microorganisms, 2021, 9, 2596.	1.6	13
475	Myocarditis complicating ethylene glycol poisoning in the absence of neurological features. Postgraduate Medical Journal, 1988, 64, 867-870.	0.9	12
476	In vitro activity of BMS-181184 compared with those of fluconazole and amphotericin B against various candida spp. Antimicrobial Agents and Chemotherapy, 1996, 40, 2229-2231.	1.4	12
477	Variation in morphotype, karyotype and DNA type of fluconazole resistant Candida albicans from an AIDS patient. Journal of Infection, 1998, 36, 57-62.	1.7	12
478	Discrepancies associated with the measurement of itraconazole serum concentrations by bioassays. Journal of Antimicrobial Chemotherapy, 1999, 44, 577-578.	1.3	12
479	Interactions of human phagocytes with mouldsFusariumspp. andVerticilliumnigrescenspossessing different pathogenicity1. Medical Mycology, 2003, 41, 503-509.	0.3	12
480	Diagnosis of IPA in HIV: the role of the chest X-ray and radiologist. European Radiology, 2004, 14, 2030-2037.	2.3	12
481	Multifocal pulmonary aspergillomas: case series and review. Annals of the New York Academy of Sciences, 2012, 1272, 58-67.	1.8	12
482	Serious fungal infections in Peru. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 943-948.	1.3	12
483	Identifying rare diseases using electronic medical records: the example of allergic bronchopulmonary aspergillosis. Pharmacoepidemiology and Drug Safety, 2017, 26, 785-791.	0.9	12
484	An evaluation of nebulised amphotericin B deoxycholate (Fungizone^{Â®}) for treatment of pulmonary aspergillosis in the UK National Aspergillosis Centre. Mycoses, 2019, 62, 1049-1055.	1.8	12
485	Estimated Burden of Fungal Infections in Namibia. Journal of Fungi (Basel, Switzerland), 2019, 5, 75.	1.5	12
486	Micafungin may be safely administered as outpatient parenteral antimicrobial therapy for chronic pulmonary aspergillosis. Mycoses, 2019, 62, 152-156.	1.8	12

#	Article	IF	Citations
487	Interferon gamma replacement as salvage therapy in chronic pulmonary aspergillosis: effects on frequency of acute exacerbation and all-cause hospital admission. Thorax, 2020, 75, 513-516.	2.7	12
488	Histoplasmosis in the Republic of Congo dominated by African histoplasmosis, Histoplasma capsulatum var. duboisii. PLoS Neglected Tropical Diseases, 2021, 15, e0009318.	1.3	12
489	Histoplasmosis in Africa: Current perspectives, knowledge gaps, and research priorities. PLoS Neglected Tropical Diseases, 2022, 16, e0010111.	1.3	12
490	The relationship between 'normal' fluid retention in women and idiopathic oedema.. Postgraduate Medical Journal, 1990, 66, 363-366.	0.9	11
491	Diagnosis of infections with Shiga-like toxin-producing Escherichia coli by use of enzyme-linked immunosorbent assays for Shiga-like toxins on cultured stool samples. Journal of Medical Microbiology, 1994, 40, 241-245.	0.7	11
492	Hyperbaric oxygen therapy in a woman who declined colostomy. Lancet, The, 1996, 348, 197.	6.3	11
493	Invasive aspergillosis in a patient with MELAS syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 68, 765-767.	0.9	11
494	Aspergillus and aspergillosisâ€“Progress on many fronts. Medical Mycology, 2006, 44, S1-S1.	0.3	11
495	Serious fungal diseases in the Republic of Uzbekistan. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 925-929.	1.3	11
496	World Health Organization Ranking of Antimicrobials According to Their Importance in Human Medicine. Clinical Infectious Diseases, 2017, 64, 986-987.	2.9	11
497	Estimated burden of fungal infections in Italy. Journal of Infection, 2018, 76, 103-106.	1.7	11
498	Estimated Burden of Serious Fungal Diseases in Serbia. Journal of Fungi (Basel, Switzerland), 2018, 4, 76.	1.5	11
499	Therapeutic drug monitoring and adverse events of delayed-release posaconazole tablets in patients with chronic pulmonary aspergillosis. Journal of Antimicrobial Chemotherapy, 2019, 74, 1056-1061.	1.3	11
500	Screening for acute disseminated histoplasmosis in HIV disease using urinary antigen detection enzyme immunoassay: A pilot study in Cameroon. Journal of Microbiological Methods, 2021, 185, 106226.	0.7	11
501	Histoplasmosis in Children; HIV/AIDS Not a Major Driver. Journal of Fungi (Basel, Switzerland), 2021, 7, 530.	1.5	11
502	Determining the burden of fungal infections in Zimbabwe. Scientific Reports, 2021, 11, 13240.	1.6	11
503	In vitro and in vivo efficacy of miramistin against drug-resistant fungi. Journal of Medical Microbiology, 2019, 68, 1047-1052.	0.7	11
504	Invasive pulmonary aspergillosis diagnosed by blood culture and successfully treated. British Journal of Diseases of the Chest, 1987, 81, 300-304.	0.5	10

#	Article	IF	Citations
505	Eradication of Low-Level Methicillin-Resistant Staphylococcus aureus Skin Colonization with Topical Mupirocin. Infection Control and Hospital Epidemiology, 1988, 9, 261-263.	1.0	10
506	A dose comparison study of a new triazole antifungal (D0870) in HIV-positive patients with oral candidiasis. Aids, 1997, 11, 759-763.	1.0	10
507	Treatment of HIV-related fluconazole-resistant oral candidosis with D0870, a new triazole antifungal. Aids, 1998, 12, 411-416.	1.0	10
508	Termination of development of D0870. Journal of Antimicrobial Chemotherapy, 2001, 47, 720-721.	1.3	10
509	Detrimental effect of propylene glycol on natural killer cell and neutrophil function. Journal of Pharmacy and Pharmacology, 2011, 39, 236-238.	1.2	10
510	Acute Aspergillus pneumonia associated with mouldy tree bark-chippings, complicated by anti-glomerular basement membrane disease causing permanent renal failure. Medical Mycology Case Reports, 2013, 2, 125-127.	0.7	10
511	Serious fungal infections in Ecuador. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 975-981.	1.3	10
512	Nebulised N-Acetylcysteine for Unresponsive Bronchial Obstruction in Allergic Brochopulmonary Aspergillosis: A Case Series and Review of the Literature. Journal of Fungi (Basel, Switzerland), 2018, 4, 117.	1.5	10
513	Estimating the Burden of Serious Fungal Infections in Uruguay. Journal of Fungi (Basel, Switzerland), 2018, 4, 37.	1.5	10
514	Burden of Severe Fungal Infections in Burkina Faso. Journal of Fungi (Basel, Switzerland), 2018, 4, 35.	1.5	10
515	Risk factors for relapse of chronic pulmonary aspergillosis after discontinuation of antifungal therapy. Clinical Infection in Practice, 2020, 5, 100015.	0.2	10
516	Effect of patient immunodeficiencies on the diagnostic performance of serological assays to detect Aspergillus-specific antibodies in chronic pulmonary aspergillosis. Respiratory Medicine, 2021, 178, 106290.	1.3	10
517	Fungal asthma among Ugandan adult asthmatics. Medical Mycology, 2021, 59, 923-933.	0.3	10
518	Serious fungal disease incidence and prevalence in Indonesia. Mycoses, 2021, 64, 1203-1212.	1.8	10
519	Chronic pulmonary aspergillosis in patients with active pulmonary tuberculosis with persisting symptoms in Uganda. Mycoses, 2022, 65, 625-634.	1.8	10
520	Anti-Cryptococcus neoformans antibodies during cryptococcosis in patients with the acquired immunodeficiency syndrome. Serodiagnosis and Immunotherapy in Infectious Disease, 1995, 7, 181-188.	0.2	9
521	Comparison of three methods for in vitro susceptibility testing of Candida species with flucytosine. Journal of Antimicrobial Chemotherapy, 2003, 51, 297-304.	1.3	9
522	National trends in incidence, prevalence and disability-adjusted life years of invasive aspergillosis in Iran: a systematic review and meta-analysis. Expert Review of Respiratory Medicine, 2019, 13, 1121-1134.	1.0	9

#	Article	IF	Citations
523	Deciphering Aspergillus fumigatus cyp51A-mediated triazole resistance by pyrosequencing of respiratory specimens. Journal of Antimicrobial Chemotherapy, 2020, 75, 3501-3509.	1.3	9
524	Diagnostic dilemma in COVID-19-associated pulmonary aspergillosis. Lancet Infectious Diseases, The, 2021, 21, 767.	4.6	9
525	Skin prick reactivity among asthmatics in East Africa. World Allergy Organization Journal, 2020, 13, 100130.	1.6	9
526	Estimated Burden of Serious Fungal Infections in Jamaica. West Indian Medical Journal, 2015, 64, 245-9.	0.4	9
527	Defective Interferon-Gamma Production Is Common in Chronic Pulmonary Aspergillosis. Journal of Infectious Diseases, 2022, 225, 1822-1831.	1.9	9
528	Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statement. European Respiratory Journal, 2022, 59, 2102950.	3.1	9
529	Efficacy of LD Bio Aspergillus ICT Lateral Flow Assay for Serodiagnosis of Chronic Pulmonary Aspergillosis. Journal of Fungi (Basel, Switzerland), 2022, 8, 400.	1.5	9
530	Temperature-dependent expression of elastase inAspergillusspecies. Medical Mycology, 1993, 31, 455-458.	0.3	8
531	Aspergillus Tracheobronchitis. Clinical Infectious Diseases, 1994, 19, 1176-1177.	2.9	8
532	Prevalence of phthioic acid inAspergillusspecies. Medical Mycology, 1997, 35, 143-145.	0.3	8
533	Activity of pradimicin BMS-181184 against Aspergillus spp. International Journal of Antimicrobial Agents, 1999, 12, 267-269.	1.1	8
534	Aspergillus fumigatus allergen expression is coordinately regulated in response to hydrogen peroxide and cyclic AMP. Clinical and Molecular Allergy, 2010, 8, 15.	0.8	8
535	Itraconazole associated quadriparesis and edema: a case report. Journal of Medical Case Reports, 2011, 5, 140.	0.4	8
536	A public resource for metabolic pathway mapping ofAspergillus fumigatusAf293. Medical Mycology, 2011, 49, S114-S119.	0.3	8
537	Posaconazole responsive cerebral aspergillosis in an immunocompetent adult. Journal of Clinical Neuroscience, 2014, 21, 1825-1827.	0.8	8
538	Aspergillus nodules in chronic granulomatous disease attributable to Aspergillus ochraceus. Medical Mycology Case Reports, 2017, 17, 31-33.	0.7	8
539	Subacute Invasive Aspergillosis Associated With Sorafenib Therapy for Hepatocellular Carcinoma. Clinical Infectious Diseases, 2018, 67, 156-157.	2.9	8
540	An Estimate of the Burden of Fungal Disease in Norway. Journal of Fungi (Basel, Switzerland), 2018, 4, 29.	1.5	8

#	Article	IF	Citations
541	Estimated burden of fungal infections in Sweden. Mycoses, 2019, 62, 1043-1048.	1.8	8
542	The role of medical mycology societies in combating invasive fungal infections in lowâ€•and middleâ€•income countries: A Nigerian model. Mycoses, 2019, 62, 16-21.	1.8	8
543	European confederation of medical mycology expert consultâ€”An ECMM excellence center initiative. Mycoses, 2020, 63, 566-572.	1.8	8
544	Evaluation of an Aspergillus IgG/IgM lateral flow assay for serodiagnosis of fungal asthma in Uganda. PLoS ONE, 2021, 16, e0252553.	1.1	8
545	The Treatment of Oropharyngeal Candidiasis in HIV-infected Patients with Oral Amphotericin B Suspension. AIDS Patient Care and STDs, 1998, 12, 625-627.	1.1	7
546	Candida glabrata Oesophagitis in a Patient Without HIV Infection. European Journal of Clinical Microbiology and Infectious Diseases, 2000, 19, 561-562.	1.3	7
547	Sub-cutaneous phaeohyphomycosis caused byCladophialophora devriesiiin a United Kingdom resident. Medical Mycology, 2006, 44, 553-556.	0.3	7
548	Mixed mould species in laboratory cultures of respiratory specimens: how should they be reported, and what are the indications for susceptibility testing?: Table 1. Journal of Clinical Pathology, 2011, 64, 543-545.	1.0	7
549	Editorial Commentary: Prophylactic Echinocandin: Is There a Subgroup of Intensive Care Unit Patients Who Benefit?. Clinical Infectious Diseases, 2014, 58, 1227-1229.	2.9	7
550	Comment on: Antifungal therapy: drugâ€“drug interactions at your fingertips. Journal of Antimicrobial Chemotherapy, 2016, 71, 2062.1-2062.	1.3	7
551	Aspergillus nigerinfection in an immunosuppressed patient confined solely to the brain. BMJ Case Reports, 2017, 2017, bcr2016218658.	0.2	7
552	An Estimate of Severe and Chronic Fungal Diseases in the Republic of Kazakhstan. Journal of Fungi (Basel, Switzerland), 2018, 4, 34.	1.5	7
553	Fungal Diseases in Taiwanâ€”National Insurance Data and Estimation. Journal of Fungi (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock 1	1.5	7
554	Detection of Pneumocystis jirovecii by quantitative real-time PCR in oral rinses from Pneumocystis pneumonia asymptomatic human immunodeficiency virus patients. Journal De Mycologie Medicale, 2019, 29, 107-111.	0.7	7
555	Intravenous therapy for chronic pulmonary aspergillosis: A systematic review and metaâ€•analysis. Mycoses, 2020, 63, 921-927.	1.8	7
556	Current burden of serious fungal infections in Republic of Congo. Mycoses, 2020, 63, 543-552.	1.8	7
557	Serious fungal diseases in Democratic Republic of Congo â€“ Incidence and prevalence estimates. Mycoses, 2021, 64, 1159-1169.	1.8	7
558	From culturomics to metagenomics: the mycobiome in chronic respiratory diseases. , 2019, , 88-118.		7

#	Article	IF	Citations
559	Estimating the Burden of Fungal Diseases in Israel. Israel Medical Association Journal, 2015, 17, 374-9.	0.1	7
560	Idiopathic oedema and diuretics. Postgraduate Medical Journal, 1987, 63, 25-26.	0.9	6
561	Immunoassay of Aflatoxin in Food and Human Tissue. Toxin Reviews, 1989, 8, 69-79.	1.5	6
562	Cost implications of alternative treatments for AIDS patients with cryptococcal meningitis. Journal of Infection, 1992, 24, 212-213.	1.7	6
563	In-vitro activity of D0870, a new triazole antifungal drug, in comparison with fluconazole and itraconazole against Aspergillus fumigatus and Candida krusei. Journal of Antimicrobial Chemotherapy, 1997, 39, 731-736.	1.3	6
564	Does One Voriconazole Breakpoint Suit All Candida Species?. Journal of Clinical Microbiology, 2007, 45, 2093-2094.	1.8	6
565	Successful long-term terbinafine therapy in an asthmatic patient with Aspergillus sensitization and bronchiectasis. Medical Mycology Case Reports, 2017, 16, 31-33.	0.7	6
566	Linking calcium signaling and mitochondrial function in fungal drug resistance. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 1254-1256.	3.3	6
567	Impact of high baseline Aspergillus-specific IgG levels on weight and quality-of-life outcomes of patients with chronic pulmonary aspergillosis. Medical Mycology, 2020, 58, 1000-1004.	0.3	6
568	Performance of LDBio Aspergillus WB and ICT Antibody Detection in Chronic Pulmonary Aspergillosis. Journal of Fungi (Basel, Switzerland), 2021, 7, 311.	1.5	6
569	Opportunistic fungal infections in persons living with advanced HIV disease in Lagos, Nigeria; a 12-year retrospective study. African Health Sciences, 2020, 20, 1573-81.	0.3	6
570	Estimated Burden of Fungal Infections in Oman. Journal of Fungi (Basel, Switzerland), 2021, 7, 5.	1.5	6
571	Skin rash after triple vaccine.. Archives of Disease in Childhood, 1987, 62, 510-511.	1.0	5
572	Assessment of Therapeutic Response of Oropharyngeal and Esophageal Candidiasis in AIDS with Use of a New Clinical Scoring System: Studies with D0870. Clinical Infectious Diseases, 1999, 28, 587-596.	2.9	5
573	Use of the 6-methylsalicylic-acid-synthase gene as a discriminating marker betweenaspergillus terreus andAspergillus flavipes. Folia Microbiologica, 1999, 44, 503-509.	1.1	5
574	Optimising antifungal therapy for individual patients. Internal Medicine Journal, 2004, 34, 147-149.	0.5	5
575	Invasive pulmonary aspergillosis with spontaneous resolution and the diagnostic utility of PCR from tissue specimens. Journal of Infection, 2004, 49, 136-140.	1.7	5
576	Audit of laboratory mycology services for the management of patients with fungal infections in the northwest of England. Journal of Clinical Pathology, 2006, 59, 759-763.	1.0	5

#	Article	IF	Citations
577	Reply to Verweij et al. Clinical Infectious Diseases, 2007, 44, 1667-1668.	2.9	5
578	Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. Journal of Antimicrobial Chemotherapy, 2012, 67, 1304-1304.	1.3	5
579	Opportunistic and Systemic Fungi. , 2017, , 1681-1709.e3.		5
580	Acute kidney injury: an unusual complication of posaconazole use. Journal of Chemotherapy, 2018, 30, 380-383.	0.7	5
581	Optimising the cut-off of the Bordier Aspergillus IgG ELISA for the diagnosis of chronic pulmonary aspergillosis. Journal of Microbiological Methods, 2020, 176, 106021.	0.7	5
582	Tackling cryptococcal meningitis in Nigeria, one-step at a time; the impact of training. PLoS ONE, 2020, 15, e0235577.	1.1	5
583	The challenge of access to refined fungal diagnosis: An investment case for low- and middle-income countries. Journal De Mycologie Medicale, 2021, 31, 101140.	0.7	5
584	Is an azoleâ€resistant Aspergillus hotspot emerging in <scp>Southâ€East</scp> Asia?. Environmental Microbiology, 2021, 23, 7275-7277.	1.8	5
585	The Global Incidence of Fungal Keratitis. SSRN Electronic Journal, 0, , .	0.4	5
586	Clinical Features of Peritoneal Tuberculosis. Journal of Infectious Diseases, 1989, 160, 344-345.	1.9	4
587	High Serum Concentrations of Aflatoxin in Nepal as Measured by Enzyme-Linked Immunosorbent Serum Assay. Human and Experimental Toxicology, 1990, 9, 143-146.	1.1	4
588	Evolving Etiology of Fungal Infection in the 1990s. Infectious Diseases in Clinical Practice, 1994, 3, S50-S55.	0.1	4
589	Mycobacterium chelonae finger infection associated with Raynaud's phenomenon. Annals of the Rheumatic Diseases, 2004, 63, 1178-1179.	0.5	4
590	A case of spotted fever group rickettsiosis imported into the United Kingdom and treated with ciprofloxacin: a case report. Journal of Medical Case Reports, 2008, 2, 98.	0.4	4
591	Sarcoidosis and aspergillosis: a tough combination. European Respiratory Journal, 2017, 49, 1700574.	3.1	4
592	The Burden of Serious Fungal Infections in Kyrgyzstan. Journal of Fungi (Basel, Switzerland), 2019, 5, 66.	1.5	4
593	The Burden of Serious Fungal Infections in Tajikistan. Journal of Fungi (Basel, Switzerland), 2019, 5, 68.	1.5	4
594	Integration of fungal diseases into health systems in Latin America. Lancet Infectious Diseases, The, 2020, 20, 890-892.	4.6	4

#	Article	IF	Citations
595	The burden of serious fungal infections in Sierra Leone: a national estimate. Therapeutic Advances in Infectious Disease, 2021, 8, 204993612110279.	1.1	4
596	BronchUK: protocol for an observational cohort study and biobank in bronchiectasis. ERJ Open Research, 2021, 7, 00775-2020.	1.1	4
597	Lung microbiome is associated with asthma severity in fungal associated asthma. , 2015, , .		4
598	WHOLE BLOOD EXCHANGE AS TREATMENT FOR LEGIONELLOSIS. Lancet, The, 1987, 329, 227.	6.3	3
599	Neurospora sitophila Pulmonary Infection in a Patient with AIDS. AIDS Patient Care and STDs, 1997, 11, 223-226.	1.1	3
600	Cutaneous childhood sarcoidosis--a rare disease refractory to treatment. British Journal of Rheumatology, 2003, 42, 1570-1571.	2.5	3
601	Clinical Research in the Lay Press: Irresponsible Journalism Raises a Huge Dose of Doubt. Clinical Infectious Diseases, 2006, 43, 1031-1039.	2.9	3
602	In vitro susceptibility of non-Aspergillus allergenic fungal species to azoles. Journal of Antimicrobial Chemotherapy, 2009, 63, 834-836.	1.3	3
603	Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy--author's response. Journal of Antimicrobial Chemotherapy, 2012, 67, 3017-3017.	1.3	3
604	Reply to "Insufficient Demonstration of Long-Term Stability of Aspergillus Galactomannan". Journal of Clinical Microbiology, 2014, 52, 4119-4119.	1.8	3
605	Chronic pulmonary aspergillosis following pulmonary embolism. Medical Mycology Case Reports, 2019, 23, 20-22.	0.7	3
606	Recovery from Copperhead Snake Envenomation: Role of Age, Sex, Bite Location, Severity, and Treatment. Journal of Medical Toxicology, 2020, 16, 17-23.	0.8	3
607	Fungal infections in transplant recipients: pros and cons of immunosuppressive and antimicrobial treatment. Lancet Microbe, The, 2021, 2, e6-e8.	3.4	3
608	Impact of Changes of the 2020 Consensus Definitions of Invasive Aspergillosis on Clinical Trial Design: Unintended Consequences for Prevention Trials?. Open Forum Infectious Diseases, 2021, 8, ofab441.	0.4	3
609	Chronic Aspergillosis. , 0, , 319-331.		3
610	Prospective Evaluation of Positivity Rates of Aspergillus-Specific IgG and Quality of Life in HIV-Negative Tuberculosis Patients in Lagos, Nigeria. Frontiers in Cellular and Infection Microbiology, 2022, 12, 790134.	1.8	3
611	Current situation of fungal diseases in Eritrea. Mycoses, 0, , .	1.8	3
612	FURTHER PROBLEMS WITH THEOPHYLLINE. Lancet, The, 1984, 323, 223.	6.3	2

#	Article	IF	Citations
613	The treatment of invasive aspergillosis. Infectious Diseases Newsletter (New York, N Y), 1991, 10, 65-69.	0.2	2
614	Time to finish with "AIDS"?. Lancet, The, 1992, 339, 1298.	6.3	2
615	Invasive pulmonary aspergillosis 10 years post bone marrow transplantation: a case report. Journal of Medical Case Reports, 2009, 3, 26.	0.4	2
616	Does Itraconazole Improve Quality of Life in Severe Asthma with Fungal Sensitization?. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 192-192.	2.5	2
617	Invasive Aspergillosis in a patient with Asthma post H1N1 PneumoniaD Nayar1, Cook P1, Lim L1, Allison D1, Denning D2County Durham and Darlington Foundation Trust1National Aspergillosis Centre, University Hospital of South Manchester2. Journal of Infection, 2011, 63, e103-e104.	1.7	2
618	Gastroesophageal Reflux Disease and Pulmonary Diseases Associated with Aspergillosis: Is There a Connection?. Mycopathologia, 2017, 182, 1125-1129.	1.3	2
619	Human Fungal Infections in Kuwaitâ€"Burden and Diagnostic Gaps. Journal of Fungi (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T f	2.5	2
620	Attainment of therapeutic posaconazole serum levels during co-administration with rifampicin. Journal of Global Antimicrobial Resistance, 2020, 23, 284-285.	0.9	2
621	The incidence of cutaneous squamous cell carcinoma in patients receiving voriconazole therapy for chronic pulmonary aspergillosis. Naunyn-Schmiedeberg's Archives of Pharmacology, 2020, 393, 2233-2237.	1.4	2
622	The burden of serious fungal infections in Azerbaijan. Therapeutic Advances in Infectious Disease, 2021, 8, 204993612110439.	1.1	2
623	Drugâ€"drug interaction database for safe prescribing of systemic antifungal agents. Therapeutic Advances in Infectious Disease, 2021, 8, 204993612110106.	1.1	2
624	Updated estimated incidence and prevalence of serious fungal infections in Trinidad and Tobago. IJID Regions, 2021, , .	0.5	2
625	Estimated Burden Of Serious Fungal Infections In Togo. Mycoses, 2021, 64, 1535-1541.	1.8	2
626	Prevalence of Aspergillus fumigatus skin positivity in adults without an apparent/known atopic disease in Uganda. Therapeutic Advances in Infectious Disease, 2021, 8, 204993612110390.	1.1	2
627	Aspergillus fumigatus catalases: cloning of an Aspergillus nidulans catalase B homologue and evidence for at least three catalases. , 0, .		2
628	Unravelling the Molecular Identification and Antifungal Susceptibility Profiles of Aspergillus spp. Isolated from Chronic Pulmonary Aspergillosis Patients in Jakarta, Indonesia: The Emergence of Cryptic Species. Journal of Fungi (Basel, Switzerland), 2022, 8, 411.	1.5	2
629	In vitro activity of saperconazole (R66 905) compared with amphotericin B and itraconazole againstAspergillus species. European Journal of Clinical Microbiology and Infectious Diseases, 1991, 10, 49-49.	1.3	1
630	Reply to Troke and Hitchcock's letter. Journal of Infection, 1994, 28, 225-227.	1.7	1

#	Article	IF	Citations
631	Advances in invasive fungal infection and antifungal therapy: Introduction. Clinical Microbiology and Infection, 2001, 7, vi.	2.8	1
632	Comment on: Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model. Journal of Antimicrobial Chemotherapy, 2015, 70, 633-633.	1.3	1
633	Diagnosis of chronic pulmonary aspergillosis (CPA) complicating pulmonary tuberculosis by chest X-ray. , 2018, , .		1
634	Standardization of Aspergillus IgG diagnostic cutoff in Nigerians. Therapeutic Advances in Infectious Disease, 2021, 8, 204993612110501.	1.1	1
635	Burden of serious fungal infections in Honduras. Mycoses, 2022, 65, 429-439.	1.8	1
636	Estimated Incidence and Prevalence of Serious Fungal Infections in Morocco. Journal of Fungi (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.5	1
637	COLOURING AGENTS IN MEDICINE FOR ASTHMATIC CHILDREN. Lancet, The, 1985, 325, 461-462.	6.3	0
638	ARREST OF A DRUG DEALER IN HOSPITAL. Lancet, The, 1985, 326, 336.	6.3	0
639	Pulmonary infection in the immunocompromised host. Current Opinion in Infectious Diseases, 1990, 3, 207-215.	1.3	0
640	Evolving Etiology of fungal Infection in the 1990s. Infectious Diseases in Clinical Practice, 1994, 3, s56.	0.1	0
641	Early management of community-acquired asthma. Respiratory Medicine, 1994, 88, 73-74.	1.3	0
642	Acute meningoâ€encephalitis in pregnancyâ€”a problem of differential diagnosis. European Journal of Neurology, 1996, 3, 267-271.	1.7	0
643	Partial 16S rDNA analysis of oral Treponema. Reviews in Medical Microbiology, 1997, 8, S25.	0.4	0
644	Early diagnosis of invasive aspergillosis. Lancet, The, 2000, 355, 2076.	6.3	0
645	Standards of care for invasive fungal infections â€“ Authors' reply. Lancet Infectious Diseases, The, 2003, 3, 402-403.	4.6	0
646	Book Review M.A. Klich, Identification of Common Aspergillus Species, ASM Press, Washington, DC, 2002, 116 pp., $39.95.. Mycopathologia, 2005, 159, 89-89.	1.3	0
647	RÃ©sistance dÂ´Aspergillus fumigatus Ã plusieurs dÃ©rivÃ©s azolÃ©s. Journal De Mycologie Medicale, 2007, 17, S11-S15.	0.7	0
648	A 27-Year-Old Woman With Acute, Severe Asthma Who Developed Respiratory Failure. Chest, 2010, 137, 724-727.	0.4	0

#	Article	IF	Citations
649	Cavitary Pulmonary Lesion In Allergic Bronchopulmonary Aspergillosis Successfully Treated With Posaconazole. , 2012, , .		0
650	Novel therapeutic options for invasive fungal infections. International Journal of Antimicrobial Agents, 2021, 58, 2100265.	1.1	0
651	Aspergillus. , 2003, , .		0
652	Polar lipids of Aspergillus fumigatus, A. niger, A. nidulans, A. flavus and A. terreus. Medical Mycology, 1998, 36, 127-134.	0.3	0
653	IL-17A in severe asthma, severe asthma with fungal sensitisation and ABPA. , 2015, , .		0
654	A.fumigatusand the bronchial epithelium - A permissive relationship?. , 2016, , .		0
655	Prophylaxis and Treatment of Invasive Aspergillosis: Who and How of Prophylaxis, Treatment, and New Therapies. Current Treatment Options in Infectious Diseases, 2020, 12, 54-70.	0.8	0
656	Evaluation of multiple open-source deep learning models for detecting and grading COVID-19 on chest radiographs. Journal of Medical Imaging, 2021, 8, 064502.	0.8	0
657	Uncommon invasive mycoses in AIDS. Aids, 1995, 9, 411-420.	1.0	0
658	Title is missing!. , 2020, 15, e0238855.		0
659	Title is missing!. , 2020, 15, e0238855.		0
660	Title is missing!. , 2020, 15, e0238855.		0
661	Title is missing!. , 2020, 15, e0238855.		0
662	Chronic Respiratory Diseases Burden and Healthcare Facilities. The Indian Journal of Chest Diseases & Allied Sciences, 2022, 64, 61-62.	0.1	0